OFFICE OF THE COMMISSIONER
ICT EMPLOYEES SOCIAL SECURITY INSTITUTION (IESSI)
Islamabad

OPEN BIDDING DOCUMENT TO CONCLUDE THE FRAMEWORK CONTRACT FOR SUPPLY OF MEDICINES INCLUDING DISPOSABLE SYRINGES AND I.V CANNULAS FOR THE YEAR 2024-25 FOR IESSI

ICT EMPLOYEES SOCIAL SECURITY INSTITUTION (HEAD OFFICE)
STREET NO 9 PLOT NO 166 SECTOR I/10-3 ISLAMABAD

The Islamabad Employees Social Security Institution, Head Office Islamabad invites sealed bids from Pharmaceutical Manufacturers/Distributors/ suppliers preferably Rawalpindi/Islamabad region / Sole Agents of Foreign Principals to conclude the Framework Contract for supply of Medicines including Disposable Syringes and I. V Cannulas for the year 2024-25 on FOR Basis at (IESSI Directorate/ head office Islamabad).

Interested bidders may download the bidding document along with detailed specifications from PPRA www.ppra.org.pk from the date of publication of tender on submission of payment of non-refundable tender fee of Rs. 3000 (Three Thousand Only). The bidding document can also be downloaded from IESSI website www.iessi.gov.pk

Bidding shall be conducted through Single Stage – Two Envelopes Bidding Procedure, as per Rule 36 (b) of Public Procurement Rules, 2004. The envelopes shall be marked as "FINANCIAL PROPOSAL" and "TECHNICAL PROPOSAL" in bold and legible letters in separate envelopes.

The Technical Bids shall accompany 500,000 Fixed Amount of Bid Security (Rule 25 of federal Procurement rules) of the estimated price in the form of CDR. Interested bidders may submit their bids by 6th January 2025 till 11:00 A.M in the office of the undersigned which shall be opened on the same day i.e by 6th January 2025 at 11:30 A.M in presence of the representatives of the participating firms (Rule 28 of PPRA, Rules 2004 as amended from time to time.

Procurement shall be governed under Public Procurement Rules 2004 (as amended from time to time). The tender can be cancelled as per Rule 33 (1).

LAST DATE OF SUBMISSION OF BID: 6th January 2025 (11.00 A.M.)

DATE OF OPENING: 6th January 2025 (11.30 A.M.)

SUBJECT: - FRAMEWORK CONTRACT FOR THE SUPPLY OF MEDICINES INCLUDING DISPOSABLE SYRINGES AND I.V CANNULAS FOR THE YEAR 2024-25

Technical specifications, Evaluation Criteria and Check List for the Open Framework Contract for the supply of medicines including disposable syringes and I.V Cannulas for the year 2024-25 are enclosed herewith.

Detail of Instructions to the bidders, General Conditions of contract, and special conditions of Contract & schedule of requirements are mentioned in the bidding document which is available at PPRA Website IESSI Website.

NO Dated Islamabad, the 2024

M/s. _

Pharmacist

This is certified that the item quoted against IESSI No.with brand name of is readily Available at following leading chain pharmacies having 20 branches in Federal/Punjab:-

S. #.	NAME OF PHARMACY	VERIFIED BY THE AUTHORIZED OFFICER/ OFFICIAL OF RESPECTIVE PHARMACY WITH NAME, DESIGNATION & STAMP.
1.		
2.		
3.		
4.		
5.		

Summary of Invoices shall be provided which could be verified accordingly. Any false claim shall be considered as fraudulent practice. Unnecessary / Irrelevant document should not be part of bid.

I Mr/Miss _____ Designation __ on the behalf of my firm hereby undertake that if above said information is left unattended or proved to be wrong on checking, the department reserves the right to reject the offer which is not challengeable in any court of law.

Signature of Authorized Person.	_
Name of Authorized Person:	_
Designation of Authorized Person:	_
Participating Firm Name:	_
Phone No.	_
Stamp:	_

PRICE SCHEDULE 2024-25

Must be attached (duly signed and stamped) with Financial Bid.

Tender No.Due on __ Manufactured by __

Address._

Manufacturing license no.Validity _

Sr no IESSI	NAME AS IN IESSI LIST	BRAND NAME OF THE OFFERED ITEM	QTY. REQUIRED	DRUG REGD. NO.	PACKING OFFERED	MRP FIXED BY F.G.	T.P. OF THE DRUG	MARKET AVERAGE T.P.	PRICE OFFERED		VALUE
									In figures	In words.	

Note:

1.Quoted price should not exceed the Trade Price.

2.Trade Price should also not exceed the Market Average Trade Price.

3.In the financial bids the arithmetical errors shall be rectified on the following basis.

a. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected.

b.If there is a discrepancy between words and figures, that quoted item will be considered cancel.

4. Furthermore, the firm is liable to furnish an affidavit to the effect that the quoted prices are not more than the prices quoted in any Government Institution.

Signature of Authorized Person. _

Name of Authorized Person: _

Designation of Authorized Person: _

Participating Firm Name: _

Phone No. _

Stamp: _

Bid Reference No:

Check List (Mandatory) for Documentary Evidence for qualification to participate in tender 2024-2025

S. #	Required Documentation	Checklist (To be initialed by the Bidder against each document)	Relevant Page Number in the Bid	Supporting Documents (To be filled by the Bidder with name of the documents that are submitted to meet the requirement)
1.	Original Tender Purchase Receipt			
2.	Original 500,000/- Bid Security of the estimated prices is attached with the Technical Bid			
3.	Drug Specification Performa duly completed			
4.	Copy of valid Drug Registration Certificates issued by the DRAP			
5.	Summary of Invoices shall be provided which could be verified accordingly. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant Document should not be part of bid.			
6.	Copy of Valid Drug Manufacturing License			
7.	Copy of Valid Drugs Sale License for Sole Agents.			
8.	Valid Letter of Authorization from manufacturers / Sole			

	Agency Agreement			
9.	Copy of NTN Certificate			
10.	Copy of complete Income Tax Return issued by FBR and audited balance sheet			
11.	Proof of Active Tax Payer			
12.	Copy of General Sales Tax Registration			
13.	Copies of valid ISO 17025 and 9001 and other certification as required in Evaluation Criteria			
14.	FDA/WHO/EMA/MDD approved quality certificates and other certificates as required in Evaluation Criteria			
15	Copy of valid GMP and other Certificate as required. In case of imported product, valid GMP certificate issued by the regulatory authority of manufacturer's country will be considered.			
16	Undertaking on Judicial/E Stamp Paper worth Rs. 100/- to the effect that None of the batch of quoted medicine has been declared Spurious / Adulterated / Sub Standard by DTLs of the Punjab / NIH Islamabad or any competent Lab of Pakistan During last two years.			

17	Undertaking on Judicial/E Stamp Paper worth Rs. 100/- to the effect that i.Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP. Non-conviction from any court of law and black listing.			
18	Thermo-log data and cold chain maintenance record must be provided by the bidders for Biological Products and Heat Sensitive Products			
19	Affidavit on Stamp Paper worth Rs. 100/- to the effect that the prices quoted in IESSI are neither more than the Trade Price nor more than The prices quoted in any Government Institution.			
20	Valid printed original price List of relevant tender period.			
21	One Samples of each medicine in Commercial Packs Note: Specifications quoted in the Technical Offer will be Verified from the samples provided with the bids.			

BIDS EVALUATION CRITERION FOR DRUGS/MEDICINES FOR MANUFACTURER

Failure to comply with any compulsory parameter / knockout clauses will result in "non-responsiveness of the bidder for quoted item". Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

.Original Receipt regarding payment of tender fees.

ii. The bidder must possess valid Drug Manufacturing License issued by DRAP (manufacturers).

i.The bidder will provide valid Drug Registration Certificate of the quoted product. The product having minimum two years' experience will be eligible.

.Valid GMP Certificate issued by the DRAP.

Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfil the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.

.Bio Similar studies of the quoted biological / Bio Tech products (in finished dosage form)

i.Undertaking on judicial/E stamp paper worth Rs. 100/- regarding "Non- Declaration of Sub Standard / Spurious/Adulterated Batch" by any notified Drug Testing Laboratory of quoted item within last two years.

ii.Undertaking on Judicial/E Stamp Paper worth Rs. 100/- to the effect that Non- cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non- conviction from any court of law and black listing.

x.One commercial packs as samples of quoted medicines for evaluation by the technical committee.

MARKING CRITERIA

Technical Evaluation Criteria for Manufacturers/distributors/suppliers

Sr. #	Description	Category Points
1	Source of API (Active Pharmaceutical Ingredient) of Quoted Item	10
i)	Original Source / Research Molecule (Affidavit on firm's letter head)	10
ii)	Source Licensed by Original or accredited by FDA/WHO/ EMA (Certificate) (The bidder must provide Import record of one year (from July 2023 to June 2024) i.e. copy of GD/LC of quoted raw material source)	08
iii)	Others Source of Raw Material with Certificate of Analysis (from July 2022 onwards	05
2	Bio Equivalence / Bio-similarity Study of Quoted Product in finished form (affidavit on Rs:100 stamp paper in case of research molecule)	10
i)	Original Manufacturer/authorize Distributor will be awarded full marks.	10
ii)	Bio equivalence/Bio-similarity Study from any of the below mentioned labs: WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. (The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).	08
3	EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS	14
(A)	Past performance of quoted product with major Government/ semi government Institutions during last two financial years i.e 2022-23 and 2023-24	07
i)	Supply of the quoted product Higher than the advertised quantity	07
ii)	Supply of the quoted product Equivalent to the advertised quantity	05
iii)	Supply of the quoted product at least 60% of advertised quantity	03

(B)	Past performance of quoted product with any social security organization during last two Financial years i.e. 2022-23 and 2023-24	07
i)	Supply of the quoted product Higher than the advertised quantity	07
ii)	Supply of the quoted product Equivalent to the advertised quantity	05
iii)	Supply of the quoted product at least 60% of advertised quantity	03
	The bidder shall provide verifiable documentary evidences like commercial sales Summary / supply order of the quoted product.	
4.	PREVIOUSLY PRE-QUALIFIED FIRMS WITH PESSI (DURING LAST THREE YEARS)	15
i)	Prequalification of the quoted product with Public Sector during last five years i.e from 2020 to 2024	10
ii)	Prequalification of the quoted product with semi Government Preferably PESSI during last five years i.e from 2020 to 2024	15
5.	FINANCIAL CAPACITY OF THE BIDDER Annual Turnover of Bidder . 2022-23 and 2023-24 The financial worth of holding company will be considered for subsidiary, subject to provision of verifiable proof	15
i)	2,001 Million or above	15
ii)	Between 1,001 to 2000 Million	10
iii)	Between 501 to 1000 Million	08
iv)	Between 300 to 500 Million	05
v)	Less than 300 Million	03
	The bidder shall provide complete Income Tax Returns issued by FBR & Audited Financial Statements (of last financial year / calendar year / any other year adopted by respective bidder as per rules).	
6.	ISO Certifications	05
i)	Valid ISO 9001	03
ii)	Valid ISO 17025	02
7.	Availability of product at major chain pharmacies having minimum 20 branches with in federal/Punjab w.e.f January 2020 to onwards (three marks for each chain pharmacy & maximum up to 15 marks). Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 15 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant document should not be part of bid.	15
8.	Production Capacity of the quoted product during last one year	05
i)	06 to 08 Batches of the quoted item	05

ii)	02 to 05 Batches of the quoted item	03
	The bidder shall provide documentary proof regarding batch history of the quoted Product	
9.	Stability Studies of the quoted product	05
i)	Accelerated Stability data of quoted item	03
ii)	Real Time stability data of quoted item	02
10.	Latest Social compliance certificate by EOBI / Social Security Registration Certificate or relevant.	06
	Total	100

NOTE: For some product where the criteria of Bio-Equivalence/Bio Similarity and API Source are not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 70%.

QUALIFYING MARKS: 70 OUT OF 100 (70%)

1. Financial bids of only "Technically Qualifying Bidders" will be prequalified and opened. Only the price offered lowest in each items shall be accepted.

BIDS EVALUATION CRITERION FOR SOLE AGENTS (DRUG / MEDICINES)

Failure to comply with any compulsory parameter / knockout clauses will result in "non-responsiveness of the bidder for quoted item". Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

MARKING CRITERIA

TECHNICAL EVALUATION CRITERIA FOR SOLE AGENT

Sr. #	Description	Category Points

1	Source of API of Quoted Item	10
i)	Original Source / Research Molecule (Affidavit on firm's letter head)	10
ii)	Source Licensed by Original or accredited by FDA/WHO/ EMA (Certificate) (The bidder must provide Import record of one year (July 2023 to June 2024) i.e. copy of GD/LC of quoted raw material source)	08
iii)	Others Source of Raw Material with Certificate of Analysis(July 2022 to Onward)	05
2	Bio Equivalence / Bio-similarity Study of Quoted Product (affidavit on Rs:100 stamp paper in case of research molecule)*	08
i)	Original Manufacturer will be awarded full marks.	08
ii)	Bio equivalence/Bio-similarity Study from any of the below mentioned labs: WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries.	06
	(The firm will attach Bio-equivalence/ Bio-Similarity certificate of the Finished product).	
3	EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS	08
	Past performance of quoted product with major Government Institutions during last two financial years i.e 2022-23 and 2023-24	04
i)	Supply of the quoted product Higher than the advertised quantity	04
ii)	Supply of the quoted product Equivalent to the advertised quantity	03
iii)	Supply of the quoted product at least 60% of advertised quantity	02
	Past performance of quoted product with PESSI during last two financial years i.e. 2022-23 and 2023-24	04
i)	Supply of the quoted product Higher than the advertised quantity	04
ii)	Supply of the quoted product Equivalent to the advertised quantity	03
iii)	Supply of the quoted product at least 60% of advertised quantity	02
	The bidder shall provide verifiable documentary evidences like commercial sales Summary / supply order of the quoted product.	
4.	PREVIOUSLY PRE-QUALIFIED FIRMS WITH PUBLIC SECTOR AND SEMI GOVERNMENT PREFERABLY PESSI (DURING LAST FIVE YEARS)	15
i)	Prequalification of the quoted product / Section with Public Sector during last five years i.e. from 2020 to 2024	10
ii)	Prequalification of the quoted product / Section with semi Government Preferably PESSI during last five years i.e. from 2020 to 2024	15

5.	Availability of product at major chain pharmacies having minimum 20 Branches with in Punjab/federal up to January 2021 to onwards (three marks for each chain pharmacy & maximum up to 15 marks). Hospital Items / Specialized Hospital Items and Anti- Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 15 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant Document should not be part of bid.	15
6.	Bidder & Manufacturer Relationship (in case of Sole Agent)	10
	Sole Agent Certificate from Manufacturer	
i)	2- 5 years	07
ii)	6 and above	10
7.	Local Market Business	
	How many years the quoted product is being marketed in Pakistan.	05
i)	2- 3 years	02
ii)	4- 5 years	03
iii)	6 years and above	05
8.	Compliance of Quality Standards of the Firm	05
i)	FDA/WHO/EMA/MDD approved	03
ii)	ISO 17025 or equivalent Certificate of manufacturing country	02
9.	Drug Testing	05
	Reports of WHO/FDA Accredited International Labs performed on the product	
i)	3 or more	05
ii)	1- 2 Labs	03
iii)	Testing by national Labs	02
10.	Export of quoted product (p.o/proforma invoice / LC copy etc) last two years	05
	Developed Countries (USA/Europe, Japan) 1- 2 countries 3- 5 countries 6 and above	05 03 05
11	List of Technical Staff (as per requirement of license)	0

.		5
12.	Temperature and humidity maintenance record of warehouse of the last one year	04
13.	Latest Social compliance certificate by EOBI / Social Security Registration Certificate or relevant	05
14.	Grand Total	100

NOTE: For some product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 70%.

QUALIFYING MARKS: 70 OUT OF 100 (70%)

2.1. Financial bids of only "Technically Qualifying Bidders" will be opened. Only the price offered lowest in each items shall be accepted.

THE ICT EMPLOYEES' SOCIAL SECURITY INSTITUTION

(HEAD OFFICE)
PLOT NO 166 STREET 9 SECTOR I/10-3 ISLAMABAD.

NEW IESSI #	ITEMS	Pack Size	Estimated quantity
	(A) ANTACIDS:		
1.	Susp. Alu Hydroxide 215mg, Mag. Hydroxide 80mg, Simethicone 25mg/5ml	120ml	5000
	Susp. Alu Hydroxide 200mg, Magnesium Oxide 100mg, Simethicone 20mg, dicyclomine HCL 2.5mg	60ml	5000
	Syp. Sodium alginate 500mg and Sodium Bicarbonate 267mg	120ml	5000
2.	Tab Ranitidine. 150mg.	10	5000
3.	Inj. Ranitidine 50mg/2ml.	10	5000
4.	Susp.Sucralfate 1gm/5ml	60ml	5000
5.	Cap.Omeprazole 20mg Pellets	100	5000
	Cap.Omeprazole 40mg Pellets	14	5000
6.	Tab. Mag. Trisilicate 500mg + Dried Alu Hydroxide250mg.	30	5000
7.	Infusion Omeprazole Sodium 42.6mg equivalent to Omeprazole 40mg (Lyophilized)	Vial	3000
8.	Tab. Famotidine 20mg	20	2000
	Tab. Famotidine 40mg	10	2000
9.	Tab.Sodamint (Sodium Bicarbonate).	30	2000

SPECIFICATIONS OF MEDICINES YEAR 2024-2025

	Tab/Cap. Esomperazole 20mg	14	5000
	Tab/Cap. Esomperazole 40mg	14	5000
	Inj. Atropine Sulphate 1mg/ml (1ml Amp).	100	1000
	Tab./ Cap. Mebevirine 135mg.		3000

10.		30	
11.	Tab. Mesalazine 400mg.	100	2000
12.	Tab.Hyoscine- N-butylbromide10mg,Paracetamol500mg.	100	3000
13.	Tab. Attapulgite 500mg	100	1000
14.	Susp. Furazolidone 25mg / 5ml, Kaolin Pectin	1	1000
15.	O.R.S. Sachet contains:NaCl 3.5gm, Sod.Citrate 2.9gm, KCL1.5gm, Dextrose Anhydrous 20gm.	30gm	5000
16.	Dioctahedral Smectite 3gm Powder.	30	3000
17.	Susp.Zinc Sulphate Monohydrate 10mg equivalent to3.64mg Elemental Zinc	60ml	1000
18.	Tab.Metronidazole 200mg	200	5000
	Tab.Metronidazole 400mg	200	5000
	Inj. Metronidazole 500mg/100ml.	Vial	2000

	Tab.Albendazole 200mg.	2	2000
	Tab.Mebendazole 100mg	60	2000
	Tab.Mebendazole 500mg	12	2000
	Susp. Albendazole 100mg/5ml.	1	2000
	Susp. Mebendazole 100mg/5ml.	30ml	2000
	Tab. Bisacodyl 5mg.	100	2000
	Bisacodyl Suppository 0.01gm	30	500
	Glycerine Suppository.	25	500
	Sodium Biphosphate 19.2gm, sodium phosphate 7.2gm, sodium contents in 120ml 4.5gm (Enema Liquid)	1	1000
	Syp. Magnesium Hydroxide 75% V/V + Liq. Paraffin 25% V/\V.	120ml	2000

19.			
20.	Inj. Interferone Alpha 3miu	1	500
	Inj. Interferone Alpha - 2b 3MIU	1	500
21.	Infusion Ornithine Aspartate 5g/10ml.	10ml	500
22.	Syp. Ornithine Aspartate 60mg, Nicotinamide 4.8mg, Riboflavin- 5mg, Phosphate Sod. 0.153mg/ml	120ml	1000
23.	Tab. Pancreatin 210 P.U. + Bromelain 35,000 PU, Dimethypolysiloxan 50mg+ Sodium Dehydrocholate 20mg + Metoclopramide 6mg.	30	1000
24.	Tab. Silymarin 200mg	20	1000
25.	Sachet Ornithine Aspartate 3gm	5	1000
26.	(a) Tab. Dimenhydrinate 50mg	100	2000
	(b) Tab.Cyclizine 50mg	100	1000
27.	(a) Inj.Dimenhydrinate50mg/ml	25	500
	(b) Inj.Cyclizine 50mg/ml.	20	500
28.	(a) Syp. Dimenhydrinate 12.5mg/5ml	1	500
29.	Inj. Ondansetron 8mg/4ml	1	500
30.	Tab. Ondansetron 8mg.	10	1000
31.	Tab. Captopril 25mg.	20	1000
32.	Tab. Atenolol 50mg.	20	500
33.	Tab. Isosorbide Dinitrate 5mg.	100	500
	Tab. Isosorbide Dinitrate 10mg.	100	500
34.	Tab. Isosorbide Mononitrate 20mg.	60	500
35.	Tab. Digoxin 250mcg.	25	500
36.	Inj. Digoxin 500mcg/2ml	5	500
37.	Tab. Diltiazem 30mg.	30	500

	Tab. Diltiazem 60mg.	30	500
	Tab./Cap. Diltiazem 90mg SR	10	500
	Tab./Cap. Diltiazem 180mg SR	10	500
38.	Tab. Nifedipine 20mg	30	500
39.	Tab. Propranolol 10mg.	50	1000
	Tab. Propranolol 40mg	50	1000
40.	Tab. Nebivolol 2.5mg	14	1500
	Tab. Nebivolol 5mg	30	1500
41.	Tab. Verapamil 40mg.	50	500
	Tab. Verapamil 80mg.	50	500
	Tab. Verapamil 240mg SR	10	500
42.	Tab. Amlodipine Besylate 5mg.	20	500
	Tab. Amlodipine Besylate 10mg.	20	500
43.	Tab. Prazosin HCL 1mg.	30	50
44.	Tab. Lisinopril 5mg.	14	50
	Tab. Lisinopril 10mg.	30	50
45.	Tab. Metoprolol 25mg.	30	500
	Tab. Metoprolol 50mg.	30	500
	Tab. Metoprolol 100mg.	30	500
46.	Tab. Aspirin 75mg (Enteric coated).	30	2000
	Tab. Aspirin 150mg (Enteric coated).	30	2000
	Tab. Aspirin 300mg (Non-Enteric coated) (Water soluble)	30	2000
47.	Tab. Losartan Potassium 50mg.	20	2000
	Tab. Losartan Potassium 100mg.	10	2000
48.	Inj. Isosorbide Dinitrate 10mg/10ml.	10	50
49.	Tab. Indapamide Hemihydrate 1.5mg SR	30	100

50.	Tab. Atorvastatin 20mg	20	1000
	Tab. Atorvastatin 40mg	10	1000
51.	Tab. Carvedilol 6.25mg	30	200
	Tab. Carvedilol 25mg	10	200
52.	Tab. Clopidogrel 75mg	14	200
	Tab. Clopidogrel 300mg	14	200
53.	Tab. Ramipril 2.5mg	28	200
	Tab. Ramipril 5mg	28	200
54.	Inj. Verapamil 2.5mg/ml	5	200
55.	Tab. Bisoprolol 2.5mg.	14	200
	Tab. Bisoprolol 5mg.	20	200
	Tab. Bisoprolol 10mg.	20	200
56.	Tab. Glyceryl Trinitrate 0.5mg	30	500
	Tab. Glyceryl Trinitrate 2.6mg	30	500
	Tab. Glyceryl Trinitrate 6.4mg	30	500
57.	Tab. Clopidogeral 75mg+ Aspirin 75mg (Acetyl Salicylic acid)	10	500
	Tab. Clopidogeral 75mg + Aspirin 150mg (Acetyl Salicylic acid)	10	500
	Tab. Nifedipine (extended relesae) 60mg.	20	500
58.	Cap.Fenofibrate 67mg	30	50
	Cap.Fenofibrate 200mg	10	50
59.	Inj.Sod.Nitroprusside 25mg/ml	5	50
60.	Inj.Isosorbide Mononitrate2mg/5ml	25	50
61.	Tab. Amlodipine 5mg + Hydrochlorthiazide 12.5mg	20	100
62.	Tab. Amlodipine 5mg + Olmesartan 20mg	20	100
	Tab. Amlodipine 5mg + Olmesartan 40mg	20	100

63.	Tab. Rosuvastatin 10mg	20	1000
64.	Tab. Losartan Potassium 50mg + Hydrochlorthiazide 12.5mg	10	1000
	Tab. Losartan Potassium 100mg + Hydrochlorthiazide 25mg	10	1000
65.	Tab. Lisinopril 10mg + Hydrochlorthiozide 12.5mg	14	500
	Tab. Lisinopril 20mg + Hydrochlorthiozide 25mg	14	500
66.	Tab. Valsartan 80mg	14	1000
	Tab. Valsartan 160mg	14	1000
67.	Tab. Valsartan 80mg + Hydrochlorthiazide 12.5mg	28	1000
	Tab. Valsartan 160mg + Hydrochlorthiazide 25mg	28	1000
68.	Tab. Valsartan 160 + Amlodipine 5mg	14	500
	Tab. Valsartan 160 + Amlodipine 10mg	14	500
69.	Tab. Valsartan 160mg + Amlopidine 5mg + Hydrochlorthiazide 25mg	28	500
	Tab. Valsartan 160mg + Amlopidine 10mg + Hydrochlorthiazide 25mg	28	500
	Tab. Valsartan 320mg + Amlopidine 10mg + Hydrochlorthiazide 25mg	14	500
70.	Inj. Labetalol 50mg	1	500
71.	Tab. Labetalol 100mg	20	500
72.	Inj.Heparin 5000 IU.	1	1000
73.	Tab.Warfarin Sod. 5mg	100	500
	Tab.Warfarin Sod. 2.5mg	30	500
	Tab.Warfarin Sod. 1mg	30	500
74.	Inj. Enoxaparin (Lowmol Wt. Heparin) 40mg	1	1000
	Inj. Enoxaparin (Lowmol Wt. Heparin) 60mg	1	1000
	Inj. Enoxaparin (Lowmol Wt. Heparin) 80mg	1	1000
75.	Tab. Rivaroxaban 10mg	10	2000
	Tab. Rivaroxaban 20mg	10	2000

	Tab. Rivaroxaban 2.5mg	14	2000
76.	Tab. Eltrombopag 25mg	28	20
	Tab. Eltrombopag 50mg	28	20
77.	Inj. Tranexamic Acid 250mg/5ml.	5	500
78.	Caps Tranexamic Acid 250mg.	20	1000
	Caps Tranexamic Acid 500mg.	20	1000
79.	Tab. Mefenamic Acid 250mg	600	2000
	Tab. Mefenamic Acid 500mg	200	2000
80.	Tab. Paracetamol 500mg.	200	5000
81.	Inj. Paracetamol 300mg/2ml	5	2000
	Inf. Paracetamol 1000mg /100ml	100ml	2000
82.	Susp. Paracetamol 120mg/5ml	120ml	2000
	Susp. Paracetamol BP 250mg/5ml.	90ml	2000
83.	Paracetamol 80mg/0.8ml Drops.	30ml	2000
84.	Tab. Ibuprofen 200mg.	500	2000
	Tab. Ibuprofen 400mg	250	2000
85.	Susp. Ibuprofen 100mg/5ml.	90ml	2000
86.	Tab. Diclofenac Sodium 50mg.	20	2000
87.	Inj. Diclofenac Sodium 75mg/3ml.	100	2000
88.	Tab. Piroxicam 10mg.	40	2000
	Cap/Tab. Piroxicam 20mg.	10	2000
89.	Diclofenac Sod. Gel.	20gm	1000
90.	Diethylamine Salicylate Gel	1	500
91.	Tab. Paracetamol 500mg + Codeine 15mg	30	1000
	Tab. Paracetamol 500mg + Codeine 30mg	30	1000
92.	Tab. Orphenadine 50mg + Paracetamol 650mg.	20	1000

93.	Tab. Tizanidine 2mg.	10	500
94.	Cap. Celecoxib 100mg	20	500
	Cap. Celecoxib 200mg.	20	500
95.	Tab. Rofecoxib 12.5mg.	10	500
96.	Tab. Meloxicam 7.5mg	10	500
	Tab. Meloxicam 15mg	10	500
97.	Tab. Trypsin & Chymotrypsin 6:1 ratio	20	500
98.	Cap. Tramadol HCL 50mg.	10	500
99.	Inj. Tramadol HCL 100mg.	5	500
100.	Tab. Naproxen Sodium 275mg equivalent Naproxen 250mg	20	500
	Tab. Naproxen Sodium 550mg equivalent Naproxen 500mg	20	500
101.	Tab. Nimesulide 100mg.	20	500
102.	Tab. Ibuprofen 200mg + Pseudoephedrine 30mg.	100	500
	Tab. Ibuprofen 400mg + Pseudoephedrine 60mg.	100	500
103.	Syp. Ibuprofen 100mg + Pseudoephedrine 15mg	120ml	500
104.	Tab. Sulphasalazine 500mg.	30	500
105.	Tab. Diclofenac Potassium 50mg.	20	500
106.	Cap.Thiocolchicoside 4mg	10	500
107.	Tab. Leflunomide 10mg	30	50
	Tab. Leflunomide 20mg	30	50
	Tab. Leflunomide 100mg	10	50
108.	Tab.Acelofenac 100mg	30	500
109.	Tab.Diclofenac Sodium 50mg,Misoprostol 200mcg	20	500
110.	Tab.Piroxicam- beta-Cyclodextrin 191.3 equal to 20mg Piroxicam.	20	500
111.	Tab. Paracetamol 500mg, Caffeine 30mg, Codeine 15mg	100	1000
112.	Tab . Etoricoxib 60mg	10	100

113.	Cap. Morphine 30mg	30	100
114.	Tab. Carbamazepine 200mg.	50	50
115.	Tab. Divalprex Sodium 250mg	100	50
	Tab. Divalprex Sodium 500mg	100	50
116.	Syp. Sodium Valproate equivalent to valproic Acid 250mg / 5ml	120ml	50
117.	Tab. Clonazepam 0.5mg.	50	50
	Tab. Clonazepam 2mg.	30	50
118.	Drops Clonazepam 0.25%.	1	50
119.	Tab. Topiramate 25mg	30	50
	Tab. Topiramate 50mg	30	50
120.	Susp. Carbamazepine 100mg/5ml	120ml	50
121.	Tab. / Cap. Gabapentin 300mg.	10	50
	Tab. / Caps. Gabapentin 100mg	10	50
122.	Tab. Oxcarbazepine 300mg	50	50
123.	Tab./Cap. Duloxetine 30mg.	10	50
	Tab./Cap. Duloxetine 60mg.	10	50
124.	Tab. Levetiracetam 250mg	30	100
	Tab. Levetiracetam 500mg	30	100
125.	Tab. Clomipramine 10mg	30	100
	Tab. Clomipramine 25mg	30	100
	Tab. Clomipramine 75mg	30	100
126.	Cap. Pregablin 150mg	14	1000
127.	Syp. Levetiracetam 100mg/ml	60ml	100
128.	Tab. Lamotrigine 50mg	30	100
129.	Tab.Cetrizine 10mg	10	1500
130.	Tab. Ebastine 10mg.		1000

		10	
131.	Tab. Levocetrizine 5mg.	10	1000
132.	Tab. Fexofenadine 60mg	10	1000
	Tab. Fexofenadine 120mg	20	1000
133.	Tab. Fexofenadine 60mg + Pseudoephedrine 120mg	10	1000
134.	Tab. Thyroxine 50mcg.	100	1000
135.	Tab. LevoThyroxine 50mcg	100	1000
	Tab. LevoThyroxine 100mcg	100	1000
136.	Inj. Epoetin alpha 2000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized).	6	5000
	Inj. Epoetin alpha 4000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized).	6	5000
	Inj. Epoetin alpha 10000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized).	1	5000
137.	Inj.Zoledronic acid 4mg	1	1000
	Inj.Zoledronic acid 5mg	1	1000
138.	Tab. Mycophenolate Mofetil 500mg.	50	5000
139.	Tab. Mycophendic Acid 180mg (as Mycophenolate Sodium)	120	500
	Tab. Mycophendic Acid 360mg (as Mycophenolate Sodium)	120	500
140.	Cap. Tacrolimus 0.5mg	30	1000
	Cap. Tacrolimus 1mg	30	1000
141.	Cap. Ampicillin 250mg.	100	500
	Cap. Ampicillin 500mg.	100	500
142.	Inj.Ampicillin 500mg.	1	500
143.	Syp. Amoxycillin 125mg/5ml.	90ml	500
144.	Cap. Amoxycillin 250mg.	100	500

	Cap. Amoxycillin 500mg.	100	500
145.	Cap. Ampicillin 250mg + Cloxacillin 250mg.	100	500
146.	Inj. Ampicillin 250mg + Cloxacillin 250mg.	1	500
147.	Tab. Amoxycillin 250mg+Clavulanic Acid 125mg	6	500
	Tab. Amoxycillin 500mg + Clavulanic Acid 125mg.	6	500
	Tab. Amoxycillin 875 + Clavulanic Acid 125mg	6	500
148.	Inj. Amoxycillin 500mg + Clavulanic Acid 100mg.	1	500
	Inj. Amoxycillin 1000mg, Clavulanic Acid 200mg.	1	500
149.	Syp. Amoxycillin 125mg, + Clavulanic Acid 31mg/5ml	90ml	500
	Syp. Amoxycillin 125mg, + Clavulanic Acid 31mg/5ml	60ml	500
	Syp. Amoxycillin 400mg, + Clavulanic Acid 57mg/5ml	35ml	500
	Syp. Amoxycillin 400mg, + Clavulanic Acid 57mg/5ml	70ml	500
150.	Tab. Trimethoprim 160mg,Sulphamethoxazole 800mg.	100	100
151.	Susp. Trimethoprim 40mg, Sulphamethoxazole 200mg/5ml.	50ml	100
152.	Tab. Ciprofloxacin 250mg.	10	500
	Tab. Ciprofloxacin 500mg.	100	500
153.	Cap. Cefixime 400mg.	10	5000
154.	Susp.Cefixime 200mg/5ml	30ml	5000
	Susp.Cefixime 100mg/5ml	60ml	5000
155.	Inj. Piperacillin 4gm+ Tazabactam 500mg.	1	1000
156.	Tab.Levofloxacin 250mg	10	1500
	Tab.Levofloxacin 500mg	10	1500
157.	Syp.Clarithromycin 125mg/5ml	60ml	1500
158.	Cap. / Tab.Azithromycin 250mg	10	1500
	Cap. / Tab.Azithromycin 500mg	6	1500
159.	Inj. Imipenam+ Cilastatin		1500

	(500mg)	1	
160.	Tab. Moxifloxacin 400mg.	5	500
161.	Inj. Meropanam 500mg	1	1500
	Inj. Meropanam 1g	1	1500
162.	Cap. Fosfomycin 500mg	10	100
163.	Inj. Insulin NPH (Isophane Insuline) 100 Units/ml.	1	5000
	Insulin Aspart - Human Insulin Analogue 100 I.U /ml	5	5000
164.	Inj. Humen Insulin 70/30 (Recombinent DNA origin).	1	5000
	Insulin Aspart / Protamine Crystalized (premix) Human Insulin Analogue 30	5	5000
	Insulin Aspart / Protamine Crystalized (premix) Human Insulin Analogue 50	5	5000
165.	Tab. Metformin 500mg.	50	5000
	Tab. Metformin 850mg	30	5000
166.	Tab. Gliclazide 30mg. MR	30	1500
	Tab. Gliclazide 60mg. MR	30	1500
167.	Inj. Insulin Plain 100 Units/ml (Regular)	1	3000
	Insulin detemir (Basal Insulin Analogue)	5	3000
168.	Tab. Acarbose 50mg.	30	300
	Tab. Acarbose 100mg.	30	300
169.	Tab.Glimepiride 2mg	20	3000
170.	Tab. Pioglitazone 15mg	14	2000
	Tab. Pioglitazone 30mg	14	2000
	Tab. Pioglitazone 45mg	14	2000
171.	Tab. Pioglitazone 15mg + Metformin 500mg.	14	2000
	Tab. Pioglitazone 15mg + Metformin 850mg.	14	2000
172.	Tab. Sitagliptin 50mg	30	3000

173.	Tab. Gliclazide 80mg + Metformin 500mg	20	3000
	Tab. Gliclazide 160mg + Metformin 1000mg	20	3000
174.	Tab. Glibenclamide 5mg + Metformin 500mg	30	2000
175.	Tab. Sitagliptin 50mg + Metformin 500mg	14	2000
176.	Tab. Vildagliptin 50mg	10	2000
177.	Vildagliptin 50mg + Metformin 850mg	14	3000
	Vildagliptin 50mg + Metformin 1000mg	14	3000
178.	Glimepride 1mg + Metformin 500mg	30	3000
	Glimepride 2mg + Metformin 500mg	30	3000
179.	Tab. Dapagliflozin 5mg	14	1500
	Tab. Dapagliflozin 10mg	14	1500
180.	Tab. Empagliflozin 10mg	14	1500

189.	Tab. Empagliflozin 25mg	14	1500
190.	Tab. Empagliflozin 5mg + Metformin 1000mg	14	1500
191.	Tab. Dapagliflozin 5mg / Metformin 1000mg	14	1500
192.	Syp. Calcium	110ml	3000

193.	(a) Tab. Calcium Gluconate.	30	3000
	(b) Tab. Calcium Lactate.	30	3000
	© Tab. Calcium Phosphate	30	3000
	(d) Tab. Calcium Carbonate.	30	3000
	(e) Tab. Calcium Acetate	30	3000
194.	Syp. Ferrous Sulphate	120ml	1500
	Syp. Ferrous Gluconate, Vitamin B1 1mg, B2 1mg, B6 1.5mg, Nicotinamide 15mg, Biotin 300mcg	120ml	1500
195.	Syp. Ferrous Sulphate with Folic Acid	1	1500
196.	(a)Tab. Ferrous Sulphate with Folic Acid.	30	1500
	(b)Tab. Ferrous Fumerate with Folic Acid.	30	1500
197.	Tab. Folic Acid 5mg.	30	5000
198.	Syp. Vit. B.Complex	120ml	1000
199.	Drops Multivitamin each 0.6ml contains:- Vitamin A 1.5mg, Vitamin D 10mcg Vitamin B1 1.5mg,Vitamin B2 1.2mg + Vitamin B6 0.5mg, Vitamin C 50mg, Nicotinamide 10mg	10ml	1000
200	Tab. Vitamin C 500mg.	40	1000
201.	Inj. Calcium Gluconate 10ml.	5	1000
202.	Tab. Multivitamin with Minerals.	30	1000
203.	Tab. Alfacalcidol 0.50mcg.	10	1000
204.	Inj. Iron Sorbitol Citric Acid Complex BP equivalent to 75mg Iron+Hydroxocobalamine Acetate 75mcg as vit-B12 + Folic Acid 750mcg.	10	500
205.	Inj. Cholecalciferol (Vit- D3) 200,000 IU equal to 5mg/ml (Amp).	1	1000
206.	Cap. Ferrous Sulphate 150mg (eq to 47mg Fe) + Folic Acid 0.5mg + Thiamine mononitrate 2mg + Riboflavine 2mg + Pyridoxine HCL		1000

	1mg+ Nicotinamide 10mg + Ascorbic Acid 50mg.	56	
207.	Tab. Calcium+ Vit- D	30	1000
208.	Inj. Iron Sucrose 20mg/ml	5	1500
209.	Tab. Iron Polymaltose Complex equal to Iron 100mg, Folic Acid 0.35mg.	10	1500
210.	Tab .Mecobalamine 500mcg	100	1500
211.	Inj. Mecobalamine 500mcg/ml	10	1500
212.	Tab./ Cap. Ossein mineral Complex 830mg (Equiv to Calcium 177.6mg, Phosphorus 82.2mg, residual mineral salt 24.8mg Collagen 224mg, other proteins 88.4mg trece elements FL, Mg, Zn, Fe, Ni, Cu) corresponding to approximate 440mg Hydroxyapatite, Vitamin D	30	2000
213.	Syp. / Susp. Per 5ml; Ossein mineral complex i.e Hydroxyapatite compd. 250 mg (equiv to calcium 53.5, Phosphorous 24.8 mg, residual mineral salts 7.5mg, collagen 87.5 mg, other proteins 20 mg, trace elements Fl, Mg, Zn, Fe, Ni, Cu), Vit D	120ml	2000
214.	Cap. Ferrous gluconate 250 mg, vits B12, vit C 50mg, folic acid 1mg, sorbitol 25 mg cooper sulphate 200mcg manganese sulphate 200 mcg.	30	2000
215.	Tab. Vitamin B1, B6, B12 Combination	100	1500
216.	(AG) EXPECTORANTS/ COUGH SUPPRESSANTS/		
217.	Tab. Montelukast 4mg	14	3000
	Tab. Montelukast 5mg	30	3000
	Tab. Montelukast 10mg.	30	300
218.	Monteleukast 4mg Powder	14	1000
219.	Cotton Bandages Guaze BPC specification Loose Woven	30mtr	50
220.	Cotton Bandages BPC 5cmx 6m.	12	50
	Cotton Bandages BPC 6.5cmx 6m.	12	50
221.	Cotton Crape Bandages 7.5cmx 4.5m.	12	50
	Cotton Crape Bandages 10cmx		50

	4.5m.	12	
222.	Cotton Wool BPC 500gm.	500gm	50
223.	Plaster of paris Bandages BPC Cal. Sulphate Hydrated 90% Kubab Gauze Cloth 10% 10cmx 2.7m.	1	50
	Bandages Plaster of paris 15cmx2.7meter.	1	50
224.	Plaster of paris, spool of 7.5cmx10m Bandage	1	50
225.	(a) Lano Paraffin Gauze Sterilized dressing impregnated with Framycetin 10cmx 10cm.	1	50
	(b)Antibiotic Tulle Dressing	1	50
	(c)Fucidin Intertulle.	1	50
	(d)Chlorinated Lime and boric acid dressing	1	50
226.	(e) Anticeptic Tulle Dressing	1	50
227.	Creamsilver Sulphadiazine 1% 50gm	1	50
	Creamsilver Sulphadiazine 1% 250mg	1	50
228.	Calcium Sodium Alignate Dressing	1	50
229.	(AN) I.V. SOLUTIONS:	1	50
230.	Inf. Sodium Chloride 4g/litre, Sod, Lactate 5.9gm/litre, potassium chloride 2.6gm per litre	1	50
231.	Inj. Dextran 6%	1	50
	Inj. Dextran 4%	1	50
232.	Inj. Dextrose 25% Amp	25ml	50
	Inj. Dextrose 25% Amp	1	50
233.	Inj. Dextrose in water 10%	1000ml	50
234.	Inj. Distilled water 5ml.	100	50
235.	Inj. Dextrose 25%	1000ml	50
236.	Inj. Dextrose 5%	1000ml	50
237.	Inj. Dextrose 5% with Normal Saline	1000ml	50
238.	Inj. Hartman's Solution	1000ml	50
239.	Inj. Mannitol 10%.		50

		1	
	Inj. Mannitol 20%.	500ml	50
240.	Inj. Potassium Chloride 15%.	1	50
241.	Inj. Normal Saline 0.9%	100ml	50
	Inj. Normal Saline 0.9%	1	50
	Inj. Normal Saline 0.9%	500ml	50
	Inj. Normal Saline 0.9%	1000ml	50
	Inj. Normal Saline 0.45%	1	50
242.	Inj. Sodium Bicarbonate 8.4%.	50ml	50
243.	Inj. Polygelline 35gm with Electrolyte per 1000ml	500ml	50
244.	Infusion contains Dextrose 5% + Sodium Chloride 0.45% (1/2 Normal Saline)	500ml	50
	Infusion contains Dextrose 5% + Sodium Chloride 0.45% (1/2 Normal Saline)	1	50
245.	Infusion contains Dextrose 4.3% + Sodium Chloride 0.18%.	500ml	50
246.	Amino acid Solution I/V	1	50
	Amino acid with electrolytes + Carbohydrate + Vitamins	1	50
247.	Lipid Solution I/V	1	50
248.	Lipid Solution I/V	1	50
249.	Infusion Containing Ca. Chloride 2H2O, Potassium Chloride 1.5gm, Sodium Acetate 3H2O 2.16gm, Dextrose Anhydrous 50gm, water for Inj.)	1	50
250.	Peritonial Dialysis Solution.	1	50
251.	Inf. Hydroxyethyl Starch (HES2000/0.5) 6% + Sodium Chloride 9gm/litre	1	50
252.	Inf. Succinylated Gelatin 20gm	1	50
253.	Inj. Cyclophosphamide 200mg	1	500
	Inj. Cyclophosphamide 500mg	1	500
	Inj. Cyclophosphamide 1000mg	1	500
254.	Inj. Vincristine 1mg.		500

		1	
255.	Inj.Doxorubicin (Adriamycin) 10mg	1	500
	Inj.Doxorubicin (Adriamycin) 20mg	1	500
	Inj.Doxorubicin (Adriamycin) 50mg	1	500
256.	Inj. Daunomycin 20mg.	1	500
257.	Tab. Tamoxifen 10mg.	30	100
258.	Inj. Fluorouracil 250mg	1	500
	Inj. Fluorouracil 500mg	1	500
259.	Inj. Vinblastine Sulphate 10mg.	1	500
260.	Inj. Methotrexate 500mg	5	500
	Inj. Methotrexate 50mg	1	500
261.	Tab. Methotrexate 2.5mg	10	1000
	Tab. Methotrexate 10mg.	10	1000
262.	Inj. Cisplatinum/ Cisplatin 10mg	1	500
	Inj. Cisplatinum/ Cisplatin 25mg	1	500
	Inj. Cisplatinum/ Cisplatin 50mg	1	500
263.	Inj. Bleomycine HCL 15mg	1	500
264.	Inj. Dactinomycin 0.5mg.	1	500
265.	Inj. Cytarabine 100mg,	1	500
	Inj. Cytarabine 500mg.	1	500
266.	Inj. Dacarbazine 200mg.	1	500
267.	Inj. Etoposide 100mg.	1	500
268.	Cap. Hydroxyurea 500mg.	100	1500
269.	Tab. Megestrol Acetate 160mg.	30	1500
270.	Tab. Mercaptopurine 50mg.	30	1500
271.	Cap. Procarbazine 50mg.	20	1500
272.	Inj. Vinorelbine 50mg.	1	500

273.	Inj. Paclitaxil 30mg.	1	1500
274.	Inj. Bevacizumab 400mg	1	100
275.	Tab Cyproterone Acetate 50mg	50	100
276.	Inj. Epirubicin HCL 10mg.	1	50
	Inj. Epirubicin HCL 50mg.	1	50
277.	Inj. Carboplatin 50mg	1	500
	Inj. Carboplatin 200mg.	1	500
	Inj. Carboplatin 450mg.	1	500
278.	Inj. Mesna 400mg, 100mg/ml (4ml Amp).	1	100
279.	Inj. Ifosfamide 500mg.	1	100
	Inj. Ifosfamide 1000mg	1	100
280.	Inj. Gemcitabine 200mg.	1	100
	Inj. Gemcitabine 1gm.	1	100
281.	Tab. Flutamide 250mg.	100	100
282.	Inj. Goserelin Acetate 3.6mg.	1	100
283.	Inj.Topotecan 4mg	5	100
284.	Inj. Docetaxel 20mg (With Solvent).	1	100
285.	Inj. Ca.Leucovorin / Ca. Folinate/ Folinic Acid (As Calcium Salt) 50mg.	1	100
286.	Tab.Cyclophosphamide 50mg	20	1000
287.	Tab. Anastrazol 1mg	28	1000
288.	(a) Inj. Pamidronate Disodium 15mg	1	100
	(b) Inj. Pamidronate Disodium 30mg	1	100
289.	Cap. Pamidronate Disodium 100mg	3	200
290.	Inj. Filgrastim 300mcg/ml	1	100
291.	Inj.Octreotide Acetate 0.05mg	5	5
	Inj.Octreotide Acetate 0.1mg		5

		5	
	Inj.Octreotide Acetate 20mg	1	5
292.	Tab. Capecitabine 500mg	10	5
293.	Tab.Letrozole 2.5mg	30	500
294.	Inj. Trastuzumab 440mg	1	100
	Inj. Trastuzumab 600mg	1	100
295.	Tab. Chlorambucil 2mg	30	500
296.	Cap. Thalidomide 50mg	10	500
	Cap. Thalidomide 100mg	10	500
297.	Tab. Imatinab 100mg	60	300
	Tab. Imatinab 200mg	60	300
	Tab. Imatinab 400mg	30	300
298.	Tab. Sorafenib 200mg	60	200
299.	Inj. Oxaliplatin 50mg	1	100
	Inj. Oxaliplatin 100mg	1	100
300.	Cap. Lenalidomide 10mg	28	100
	Cap. Lenalidomide 25mg	21	100
301.	Tab. Melphalan 2mg	20	100
302.	Inj. Rituximab 100mg	2	50
	Inj. Rituximab 500mg	1	50
303.	Inj. Fludarabine 50mg	1	10
304.	Inj. Rho. (D) Immune Globulin (Human) 300mcg	1	100
305.	Inj. Hepatitis- B Immune Globulin 200iu/ml	1	50
306.	Tab. Telbivudine 600mg	28	100
307.	Inj. Acyclovir 500mg (Lyophilized)	10ml	50
308.	Tab. Adefovir Dipivoxil 10mg.	30	50
309.	Tab. Entecavir 0.5mg		500

		30	
310.	Tab. Tenofovir Disoproxil 300mg	30	100
311.	Inj. Remdesivir 100mg	1	200
312.	Inj. Desferrioxamine Mesylate 500mg.	10	10
313.	Tab.Penicillamine 250mg	10	10
314.	Tab.Deferasirox 400mg	30	500
	Tab.Deferasirox 100mg	30	500
315.	Inj. Protamine Sulphate 10mg/ml	1	100
316.	Anti Rabbies Vaccine	1	100
317.	Disposable Syringes 1CC Insuline	100	100
318.	Disposable Syringes 2.5CC	100	100
319.	Disposable Syringes 3CC	100	100
320.	Disposable Syringes 5CC	100	100
321.	Disposable Syringes 10CC	100	100
322.	Disposable Syringes 20CC	50	100
323.	Disposable Syringes 50CC	25	100
324.	Disposable Syringes 60CC	25	100
325.	I/V Set	25	100
326.	I.V. Cannula 14G	50	100
	I.V. Cannula 16G	50	100
	I.V. Cannula 18G	50	100
	I.V. Cannula 20G	50	100
	I.V. Cannula 22G	50	100
	I.V. Cannula 24G	50	100

INFORMATION REGARDING ISSUANCE AND

RECEIVING OF TENDER FORMS

Sr. No.	Description	Name of Officer / Official
1.	Tender Issuing officer	Medical Advisor
2.	Tender Distribution Officer/ official	Pharmacist/Procurement Officer
3.	Tender Receiving Officers	Medical Advisor/ Assistant Director Medical/ Pharmacist

INSTRUCTIONS TO BIDDERS

1. Scope of Bid: THE ICT EMPLOYEE'S SOCIAL SECURITY INSTITUTION (IESSI), invites sealed bids from Pharmaceutical Manufacturers/Sole Agents of Foreign Manufacturers to conclude the framework contract for supply of Medicines including Disposable Syringes and I.V Cannulas for IESSI Medical Outlet as per quantities and specifications described in Specifications of Medicines Year 2024-25 of the Bidding Documents. The nature of contract shall be Local Contract.
2. Source of Funds: THE ICT EMPLOYEE'S SOCIAL SECURITY INSTITUTION (IESSI), has allocated the budget from its own funds for the purchase of medicines for IESSI Hospitals/Directorates under the relevant head of Account.
3. Eligible bidders: This Invitation for Bids is open to all Manufacturers and in case of imported goods, their Sole Agents / Importer in Pakistan, for concluding the framework contract for supply of Drugs / Medicines, on Free Delivery basis to IESSI HEAD OFFICE OR DESIRED OUTLET AS PER DEMAND. The importer /sole agent must possess a valid authorization from the Foreign Principal / Manufacturer and drugs sale license issued by the competent authority in Pakistan and in case of manufacturer they should have a documentary proof of valid drugs manufacturing license. The bidder shall also have to submit a copy of valid registration certificate from Ministry of Health, Islamabad / Drug Regulatory Authority Pakistan. The bidders shall not be under a declaration of ineligibility for corrupt and fraudulent practices, declared by any Government (Federal/Provincial/District), Local Body or Public Sector Organization.
4. Corrupt Practices and Mechanism to Debar/Blacklist the Defaulted Bidder.

   4.1 The Federal Government defines Corrupt and Fraudulent Practices as "the offering, giving, receiving, or soliciting of anything of value to influence the

action of a public official or the contractor in the procurement process or in contract execution to the detriment of the procuring agency; or misrepresentation of facts in order to influence a procurement process or the execution of a contract, collusive practices among bidders (prior to or after bid submission) designed to establish bid prices at artificial, non- competitive levels and to deprive the procuring agency of the benefits of free and open competition and any request for, or solicitation of anything of value by any public official in the course of the exercise of his duty; it may include any of the following practices:

(i) coercive practice by impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence the actions of a party to achieve a wrongful gain or to cause a wrongful loss to another party;

(ii) collusive practice by arrangement between two or more parties to the procurement process or contract execution, designed to achieve with or without the knowledge of the procuring agency to establish prices at artificial, non- competitive levels for any wrongful gain;

(iii) corrupt practice by offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence the acts of another party for wrongful gain;

(iv) fraudulent practice by any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(v) obstructive practice by harming or threatening to harm, directly or indirectly, persons or their property to influence their participation in a procurement process, or affect the execution of a contract or deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements before investigators in order to materially impede an investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or acts intended to materially impede the exercise of inspection and audit rights;

4.2 Indulgence in corruption and fraudulent practices is liable to result in rejection of Bids, cancellation of contracts, debarring and blacklisting of the Bidder, for a stated or indefinite period of time.

4.3 The following are the events which would lead to initiate under the PPRA Rules 2004 Blacklisting / Debarment process;

.Submission of false fabricated / forged documents for procurement in tender.

i.Not attaining required quality of work.

iii. Inordinate tardiness in accomplishment of assigned/agreed responsibilities / contractual obligations resulting loss to procuring

agency.

v.Non- execution of work as per terms & condition of contract.

v. Any unethical or unlawful professional or business behavior detrimental to good conduct and integrity of the public procurement process.

vi.Involvement in any sort of tender fixing.

vii.Persistent and intentional violation of important conditions of contract

viii. Non- adherence to quality specification despite being importunately pointed out.

ix. Security consideration of the State i.e., any action that jeopardizes the security of the State or good repute of the procuring agency.

5. PROCEDURE: The procedure mentioned in Public Procurement Rules 2004 will be followed.

6. Eligible Goods and Services: For these purposes, the term "Goods" includes any Goods that are the subject of this Invitation for Bids as defined in General Condition of Contract 1(c) and the term "Services" shall include related services as defined in General Condition of Contract Clause 1(e).

7. Cost of Bidding: The bidder shall bear all costs associated with the preparation and submission of its bid, and the Procuring Agency shall in no case be responsible or liable for those costs, regardless of the manner or outcome of the bidding process.

8. Bidding for Selective Items.

8.1 A Bidder, if he so chooses, can bid for selective items from the list of goods provided in the Specifications of Medicines for the year 2024- 25. A Bidder is also at a liberty to bid for all the items Specifications of Medicines for the year 2024- 25. However, Bidders

Cannot bid for partial quantities of any item mentioned in Specifications of Medicines for the year 2024- 25. The bid must be for the total quantity of an item required in the Specifications of Medicines for the year 2022- 23.

THE BIDDING PROCEDURE

9. Single stage –two envelopes bidding procedure shall be applied

9.1 Single stage –two envelopes bidding procedure shall be applied:-

i. the bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals;

.the envelopes shall be marked as "Financial Proposal" and "Technical Proposal";

.in the first instance, the "Technical Proposal" shall be opened and the envelope marked as "Financial

oposal" shall be retained unopened in the custody of the procuring agency;
the procuring agency shall evaluate the technical proposal in the manner prescribed in advance, without reference to the price and shall reject any proposal which does not conform to the specified requirements;
during the technical evaluation no amendments in the technical proposal shall be permitted;
after the evaluation and approval of the technical proposals, the procuring agency shall open the financial proposals of the technically accepted bids, publically at a time, date and venue announced and communicated to the bidders in advance, within the bid validity period;
The financial proposal of the bids found technically non-responsive shall be retained unopened and shall be returned on the expiry of the grievance period or the decision of the complaint, if any, filed by the non-responsive bidder, whichever is later: provided that the procuring agency may return the sealed financial proposal earlier if the disqualified or non-responsive bidder, contractor or consultant submits an affidavit, through an authorized representative, to the effect that he is satisfied with the proceedings of the procuring agency]; and
the successful lowest bidder in each items shall be awarded the contract;

THE BIDDING DOCUMENTS

10. Content of Bidding Documents

i. The goods required, applicable bidding procedures, and Contract Terms are prescribed in the Bidding Documents. In addition to the invitation for Bids, the Bidding Documents include:-

a. Instructions to bidders;
b. General Conditions of Contract;
c. Special Conditions of Contract;
d. Schedule of Requirements.
e. Delivery time, completion schedule and price schedule.
f. Contract Form;
g. Manufacturer's Authorization Form;
h. Bid Form;
i. Bid Evaluation Criteria
j. Technical specification comprising list of medicines and Drug Specification Proforma.

ii. The bidder is expected to examine all instructions, forms, terms, and specifications in the bidding documents.

iii Failure to furnish all information required by the bidding documents or to submit a bid not substantially responsive to the bidding documents in every respect shall be at the bidder's risk and may result in the rejection of its bid.

11. Clarification of Bidding Documents: (1) No bidder shall be allowed to alter or modify his bid after the closing time for the submission of

the bids.

(2) The procuring agency may, if necessary after the opening of the bids, seek and accept such clarifications of the bid as do not change the substance of the bid.

(3) Any request for clarification in the bid, made by the procuring agency and its response, shall invariably be in writing.

PREPARATION OF BIDS

12. Language of Bid: The bid prepared by the bidder, as well as all correspondence and documents relating to the bid exchanged by the bidder and the Procuring Agency shall be written in English. Supporting documents and printed literature furnished by the bidder may be in another language provided they are accompanied by an accurate translation in English, in which case, for purposes of interpretation of the Bid, the translation shall govern.

13. Documents Comprising the Bid: The bid shall comprise the following components:

(a) Bid Form and Price Schedule completed in accordance with instruction to bidders (to be submitted along with financial proposal);

(b) Documentary evidence established in accordance with instruction to bidders that the bidder is eligible to bid and is qualified to perform the Contract if its bid is accepted;

(c) Documentary evidence established in accordance with instruction to bidders that the goods to be supplied by the bidder are eligible goods and conform to the bidding documents; and

(d) Bid Security, furnished in accordance with instruction to bidders.

14. Bid Form & Price Schedule: The bidder shall complete the Bid Form and an appropriate Price Schedule furnished in the bidding documents, indicating the goods to be supplied, a brief description of the goods, their strength, packing, quantity, and prices.

15. Bid Prices:

i. The bidder shall indicate on the appropriate Price Schedule the unit prices and total bid price of the goods, it proposes to supply under the Contract.

. Form of price Schedule is to be filled in very carefully, preferably typed. Any alteration / correction must be initialed and stamped. Every page is to be signed and stamped at the bottom. Serial number of the quoted item may be marked with red / yellow marker.

. The bidder should quote the prices of goods according to the strength / technical specifications as

ovided in the Form of Price Schedule and Technical Specifications. The specifications of goods, different from the demand of bid enquiry, shall straightway be rejected.

.The bidder is required to offer competitive price. All prices must include the General Sales Tax (GST) and other taxes and duties, where applicable. If there is no mention of taxes, the offered / quoted price shall be considered as inclusive of all prevailing taxes/duties. The benefit of exemption from or reduction in the GST or other taxes shall be passed on to the Procuring Agency.

.Prices offered should be for the entire quantity demanded; partial quantity offers shall straightaway be rejected. Conditional offer shall also be considered as non- responsive bidder.

.While tendering your quotation, the present trend / inflation in the rate of goods and services in the market should be kept in mind. No request for increase / decrease in price due to market fluctuation in the cost of goods and services shall be entertained.

16. Bid currencies: Prices shall be quoted in Pak Rupees.

17. Documents Establishing bidder's Eligibility and Qualification

i. The bidder shall furnish, as part of its technical bid, documents establishing the bidder's eligibility to bid and its qualifications to perform the Contract if its bid is accepted.

.The documentary evidence of the bidder's eligibility to bid shall establish to the Procuring Agency's satisfaction that the bidder, at the time of submission of its bid, is an eligible as defined under instruction to the bidders

.The documentary evidence (to be submitted along with technical proposal) of the bidder's qualifications to perform the Contract if its bid is accepted shall establish to the Procuring Agency's satisfaction:

(a) The Sole Agent / Importer shall have to produce valid letter of authorization from Foreign Principal and in case of local Manufacturer, documentary proof including valid drug manufacturing license / registration certificate, to the effect that they are the original manufacturer of the required specifications of goods, shall be provided.

(b) National Tax Number (NTN) and General Sales Tax Number (GST) with documentary proof shall have to be provided by each bidder in the tender.

(c) The bidder shall submit an affidavit on legal stamp paper of Rs. 100/- that their firm is not blacklisted on any ground by any Government (Federal/ Provincial/District), a local body or a Public Sector Organization. The bidder shall be debarred from bid on account of submission of false statement.

(d) The bidder should have minimum two- year' experience in the market. Similarly, it is mandatory that the item to be quoted by the bidder /

Manufacturer should have availability in the market minimum for the last two years. Documentary proof shall have to be provided in this regard.

(e) The bidder is required to provide with the Technical Proposal, the name of item(s) for which they have quoted their rates in the Financial Proposals.

(f) The bidder must indicate the registration number, make of country of origin / Manufacturer of the drugs, capacity of production of the firm, its financial status, batch capacity, necessary assurance of quality production, GMP / CGMP.

(g) Proof of active taxpayer

18. Documents Establishing Goods' Eligibility and Conformity to Bidding Documents:

i. The bidder shall furnish along with Technical Proposal, as part of its bid, documents establishing the eligibility and conformity to the bidding documents of all goods, which the bidder proposes to supply under the Contract.

.The documentary evidence of the eligibility of the goods shall consist of a statement in the Price Schedule of the country of origin of the goods offered which a certificate of origin issued by the Manufacturer shall confirm.

.Submission of sample:

a) The bidder must produce along with technical proposal, Two (02) samples of quoted product(s) (Commercial pack) according to the strength demand of enquiry. No technical proposal / bid shall be considered in absence of samples.

b) The representative sample(s) must be from the most recent stocks, supported by valid warranty as per Drugs Act 1976.

19. Bid security.–The bidders shall furnish a bid security equal to 500,000/- of estimated price and the original bid security shall be attached with the Technical Bid, whereas its photocopy shall be attached with the Financial Bid.

20. Bid validity.–(i) A procuring agency, keeping in view the nature of the procurement, shall subject the bid to a bid validity period.

The bids shall be valid for the period of 120- days.

(iii) Subject to sub- rule (5), a procuring agency shall ordinarily be under an obligation to process and evaluate the bids within the stipulated bid validity period but, under exceptional circumstances and for reasons to be recorded in writing, if an extension is considered necessary, all the bidders shall be

requested to extend their respective bid validity period but such extension shall not be for more than the original period of bid validity.

) A bidder who:

(a) agrees to the extension of the bid validity period shall also extend the validity of the bid bond or security for the extended period of the bid validity;

agrees to the procuring agency's request for extension of bid validity period shall not be permitted to change the substance of the bid; and

(c) does not agree to an extension of the bid validity period shall be allowed to withdraw the bid without forfeiture of the bid bond or security.

21. Extension of time for submission of bids.–If a procuring agency considers that it is necessary in public interest to extend the last date for the submission of the bids, it may, after recording reasons, do so in the manner similar to the original advertisement.

22. Format and Signing of Bid:

i. The bidder shall prepare and submit its bid along with original purchase receipt. The bid shall be typed or written in indelible ink and shall be signed by the bidder or a person or persons duly authorized by the firm. The person or persons signing the bid shall initial and stamped all pages of the bid, except for un-amended printed literature.

.Any interlineations, erasures, or overwriting shall be valid only if they are initialed and stamped by the person or persons signing the bid.

SUBMISSION OF BIDS

23. Sealing and Marking of Bids

i. All bids should be submitted in proper binding / ring binding / proper file cover.

.The envelopes shall be marked as "FINANCIAL PROPOSAL" and "TECHNICAL PROPOSAL" in bold and legible letters to avoid confusion. The inner and outer envelopes shall:

a. be addressed to the Procuring Agency at the address given in the Invitation for Bids and;

b.bear the name and number indicated in the Invitation for Bids.

.The inner envelopes shall also indicate the name and address of the bidder to enable the bid to be returned unopened in case it is declared as "non-responsive".

.If the outer as well as inner envelope is not sealed and marked as required by instruction to bidders, the Procuring Agency shall assume no responsibility for the bid's misplacement or premature opening.

24. Deadline for Submission of Bids: Bids must be submitted by the bidder and received by the Procuring Agency at the address specified under instruction to bidders, not later

than the time and date specified in the Invitation for Bids.

25. Late Bid: Any bid received by the Procuring Agency after the deadline for submission of bids prescribed by the Procuring Agency shall be rejected and returned unopened to the bidder.

26. Withdrawal of Bids: The bidder may withdraw its bid after the bid's submission and prior to the deadline prescribed for submission of bids. No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified in instruction to bidders. Withdrawal of a bid during this interval may result in the Bidder's forfeiture of its Bid Security pursuant to the instruction to bidders.

OPENING AND EVALUATION OF BIDS

27. Opening of Bids

i. The Procuring Agency shall initially open only the envelopes marked "TECHNICAL PROPOSAL" in the presence of bidders' representatives who choose to attend, at the time, on the date, and at the place specified in the Invitation for Bids. The bidders' representatives who are present shall sign the Attendance Sheet evidencing their attendance. However, the envelope marked as "FINANCIAL

PROPOSAL" shall be retained in the custody of Procuring Agency without being opened and till completion of the evaluation process. On the day of opening of technical bid the technical offer of the firms shall be signed by the members of the Institutional Tender Committee, whereas, only the envelope of the financial bids shall be signed by the members of the Institutional Tender Committee for the transparency of the procuring process.

.The bidders' names, item(s) for which they quoted their rate and such other details as the Procuring Agency, at its discretion, may consider appropriate, shall be announced at the opening of technical proposal. No bid shall be rejected at technical proposal / bid opening, except for late bids and such technical bids which shall not accompanying original 500,000/- Bid Security of the estimated price, which shall be returned unopened to the bidder. However, at the opening of Financial Proposals (the date, time and venue would be announced later on), the bid prices, and the presence or absence of requisite Bid Security and such other details as the Procuring Agency, at its discretion, may consider appropriate, shall be announced.

.The technical bids found without Bid Security shall also be returned to the bidders. However, prior to

turn to the bidder, the Chairman of the Technical Purchase Committee shall record statement / reason on such bids.

.The Procuring Agency shall prepare minutes of the bids opening (technical and financial).

28. Clarification of Bids: During evaluation of the bids, the Procuring Agency may, at its discretion, ask the bidder for a clarification of its bid. The request for clarification and the response shall be in writing, and no change in the prices or substance of the bid shall be sought, offered, or permitted

29. Preliminary Examination

i. The Procuring Agency shall examine the bids to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished, whether the documents have been properly signed, and whether the bids are generally in order.

.In the financial bids the arithmetical errors shall be rectified on the following basis. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected. If the bidder does not accept the correction of the errors, its bid shall be rejected, and its bid Security may be forfeited. If there is a discrepancy between words and figures, the amount in words shall prevail.

.The Procuring Agency may waive any minor informality, nonconformity, or irregularity in a bid which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any bidder.

.Prior to the detailed evaluation, the Procuring Agency shall determine the substantial responsiveness of each bid to the bidding documents. For purposes of these Clauses, a substantially responsive bid is one, which conforms to all the terms and conditions of the bidding documents without material deviations. Deviations from, or objections or reservations to critical provisions, such as those concerning Applicable Law, Drugs Act, Taxes & Duties and GMP practices shall be deemed to be a material deviation for technical proposals and Bid Security for financial proposals. The Procuring Agency's determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.

.If a bid is not substantially responsive, it shall be rejected by the Procuring Agency and may not subsequently be made responsive by the bidder by correction of the nonconformity.

30. Applicable Bidding Procedure

"Single stage – Two Envelops bidding procedure" shall be applied. Single Stage: Two

Envelope Bidding Procedure

Single stage two envelopes bidding procedure shall be used for procurement of such goods where the bids are to be evaluated on technical and financial grounds and the procedure for single stage two envelopes shall be:

i. the bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals;

.the envelopes shall be marked as "Financial Proposal" and "Technical Proposal";

.in the first instance, the "Technical Proposal" shall be opened and the envelope marked as "Financial Proposal" shall be retained unopened in the custody of the procuring agency;

.The procuring agency shall evaluate the technical proposal in the manner prescribed in advance, without reference to the price and shall reject any proposal which does not conform to the specified requirements;

during the technical evaluation no amendments in the technical proposal shall be permitted;

.after the evaluation and approval of the technical proposals, the procuring agency shall open the financial proposals of the technically accepted bids, publicly at a time, date and venue announced and communicated to the bidders in advance, within the bid validity period;

.the financial bids found technically nonresponsive shall be returned un- opened to the respective bidders; and the lowest evaluated bidder shall be awarded the contract;

31. Contacting the Procuring Agency: No bidder shall contact the Procuring Agency on any matter relating to its bid, from the time of the bid opening to the time the Contract is awarded. If the bidder wishes to bring additional information to the notice of the Procuring Agency, it should do so in writing. Any effort by a bidder to influence the Procuring Agency in its decisions

on bid evaluation, bid comparison, or Contract award may result in the rejection of the bidder's bid. Canvassing by any bidder at any stage of the Tender evaluation is strictly prohibited. Any infringement shall lead to disqualification.

32. Qualification & disqualification of bidders: i) The Procuring Agency shall determine to its satisfaction whether a Bidder, technically and financially qualified and even having the lowest evaluated responsive bid is qualified to perform the Contract satisfactory.

ii. The Procuring Agency shall disqualify a bidder if it finds, at any time, that the information submitted by him concerning his qualification was false and materially inaccurate or incomplete.

iii. An affirmative determination shall be a prerequisite for award of the Contract to the

Bidder. A negative determination shall result in rejection of the Bidder's bid, in which event the Procuring Agency shall proceed to the next lowest evaluated bid to make a similar determination of that Bidder's capabilities to perform satisfactorily.

33. Rejection of bids.–(1) Under Rule 33, PPRA Rules, the procuring agency may reject all bids or proposals at any time prior to the acceptance of a bid or proposal.

(2) The procuring agency shall upon request communicate to any bidder, the grounds for its rejection of all bids or proposals, but shall not be required to justify those grounds.

(3) The procuring agency shall incur no liability, solely by virtue of its invoking sub- rule (1) towards the bidders.

(4) The bidders shall be promptly informed about the rejection of the bids, if any.

34. Re- bidding.–If the procuring agency rejects all the bids under rule 33, it may proceed with the process of fresh bidding but before doing that it shall assess the reasons for rejection and may, if necessary, revise specifications, evaluation criteria or any other condition for bidders.

35. Announcement of evaluation reports.–A procuring agency shall announce the results of bid evaluation in the form of a report giving justification for acceptance or rejection of bids at least Fifteen days prior to the award of procurement contract.

AWARD OF CONTRACT

36. Acceptance of Bid and Award criteria

The Bidder whose bid is found to be most closely conforming to the Evaluation Criteria prescribed and having the lowest evaluated bid, if not in conflict with any other law, rules, regulations or policy of the FEDERAL Government, shall be awarded the Contract, within the original or extended period of bid validity.

Procuring Agency's right to vary quantities at time of award

The Procuring Agency reserves the right to increase or decrease, the quantity of goods originally specified in the Price schedule and Schedule of Requirements without any change in unit price or other terms and conditions.

Negotiations

PPRA Rules 2004 (Rule 40 of PPRA Rules 2004 as amended from time to time) shall be followed.

Notification of Award

i. Prior to the expiration of the period of bid validity, the Procuring Agency

shall notify the successful bidder in writing by registered letter, that its bid has been accepted.

he notification of award shall constitute the formation of the Contract.

40 Signing of Framework Contract

i. At the same time as the Procuring Agency notifies the successful bidder that its bid has been accepted, the Procuring Agency shall send the bidder the Contract Form provided in the bidding documents, incorporating all agreements between the Parties.

ii. Both the successful bidder and the Procuring Agency shall sign the Framework Contract (with date) on the legal stamp paper as per applicable laws, however, in case of requirement of additional paper / papers, only the yellow continuation sheet to be issued by the stamp paper vendor shall be accepted. Thereafter, the Procuring Agency shall issue Purchase Order. If the successful bidder, after completion of all Codal Formalities shows inability to sign the Framework Contract then their Bid Security shall be forfeited and the firm may be blacklisted under the PPRA Rules. In such situation, the Procuring Agency may make the award to the next lowest evaluated bidder at the risk and cost of such firms.

Performance Security.

i. On the date of signing of Contract, the successful bidder shall furnish the Performance Security (7% of total order value) in accordance with the Conditions of Contract, provided in the bidding documents. The 500,000/- bid Security would be returned to the bidder on request upon submission of Performance Security.

ii. Failure of the successful bidder to comply with the requirement of instructions to the bidders shall constitute sufficient grounds for the annulment/termination of the award and forfeiture of the bid Security, in which event the Procuring Agency may make the award to the next

lowest evaluated bidder at the risk and cost of the firm.

iii. Performance Security shall be retained for relevant financial year. The process of release of 7% performance security shall be initiated on receipt of written request from the firm after expiry of the said financial year and subject to the satisfaction performance of the firm.

Price Reasonability Certificate

i. The supplier shall certify on judicial stamp paper that the prices quoted to IESSI against the items mentioned at Tender Enquiry No.are not more than the Trade Prices as per MRP (Maximum Retail Price) fixed by the Federal

Government under Drugs Act, 1976/DRAP Act 2012 as well as prices are not more than the prices quoted to any other Government / Semi Government and Private Institutions.

All suppliers will comply with the provision of Drugs Act 1976/DRAP Act 2012

Drug Act/ DRAP Compliance.

All supplies will comply with the provision of Drugs Act, 1976/DRAP Act, 2012/ Drugs Act and rules framed there under.

Blacklisting

PPRA Rules 2004 as amended from time to time under Rule-19 issued by Federal Government shall be followed.

BIDS EVALUATION CRITERION FOR DRUGS/MEDICINES FOR MANUFACTURER

Failure to comply with any compulsory parameter / knockout clauses will result in "non-responsiveness of the bidder for quoted item". Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

i. Original Receipt regarding payment of tender fees.
ii. The bidder must possess valid Drug Manufacturing License issued by DRAP (manufacturers).

iii. The bidder will provide valid Drug Registration Certificate of the quoted product. The product having minimum two years' experience will be eligible.
iv. Valid GMP Certificate issued by the DRAP.
v. Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfil the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.
vi. Bio Similar studies of the quoted biological / Bio Tech products (in finished dosage form)
vii. Undertaking on judicial stamp paper worth Rs. 100/- regarding "Non Declaration of Sub Standard / Spurious/Adulterated Batch" by any notified Drug Testing Laboratory of quoted item within last two years.
viii. Undertaking on Judicial Stamp Paper worth Rs. 100/- to the effect that Non- cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non- conviction from any court of law and black listing.
ix. Two commercial packs as samples of quoted medicines for evaluation by the technical committee.

MARKING CRITERIA

Technical Evaluation Criteria for Manufacturers

Sr. #	Description	Category Points
1	Source of API of Quoted Item	10
i)	Original Source / Research Molecule (Affidavit on firm's letter head)	10
ii)	Source Licensed by Original or accredited by FDA/WHO/ EMA (Certificate) (The bidder must provide Import record of one year (from July 2023 to June 2024) i.e. copy of GD/LC of quoted raw material source)	08
iii)	Others Source of Raw Material with Certificate of Analysis(July 2022 to onwards)	05
2	Bio Equivalence / Bio- similarity Study of Quoted Product in finished form (affidavit on Rs:100 stamp paper in case of research molecule)	10
i)	Original Manufacturer will be awarded full marks.	10

ii)	Bio equivalence/Bio-similarity Study from any of the below mentioned labs: WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. (The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).	08
3	EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS	14
(A)	Past performance of quoted product with major Government Institutions during last two financial years i.e 2022-23 and 2023-24	07
i)	Supply of the quoted product Higher than the advertised quantity	07
ii)	Supply of the quoted product Equivalent to the advertised quantity	05
iii)	Supply of the quoted product at least 60% of advertised quantity	03
(B)	Past performance of quoted product with Public Sector during last two financial years i.e 2022-23 and 2023-24	07
i)	Supply of the quoted product Higher than the advertised quantity	07
ii)	Supply of the quoted product Equivalent to the advertised quantity	05
iii)	Supply of the quoted product at least 60% of advertised quantity	03
	The bidder shall provide verifiable documentary evidences like commercial sales summary / supply order of the quoted product.	
4.	PREVIOUSLY PRE-QUALIFIED FIRMS WITH PUBLIC SECTOR AND SEMI GOVERNMENT PREFERABLY PESSI (DURING LAST FIVE YEARS)	15
i)	Prequalification of the quoted product with Public Sector during last five years i.e from 2020 to 2024	10
ii)	Prequalification of the quoted product with Semi Government preferably PESSI during last five years i.e from 2020 to 2024	15

5.	FINANCIAL CAPACITY OF THE BIDDER Annual Turnover of Bidder (2023-24). The financial worth of holding company will be considered for subsidiary, subject to provision of verifiable proof	15
i)	2,001 Million or above	15
ii)	Between 1,001 to 2000 Million	10
iii)	Between 501 to 1000 Million	08
iv)	Between 300 to 500 Million	05
v)	Less than 300 Million	03

	The bidder shall provide complete Income Tax Returns issued by FBR & Audited Financial Statements (of last financial year / calendar year / any other year adopted by respective bidder as per rules).	
6.	ISO Certifications	05
i)	Valid ISO 9001	03
ii)	Valid ISO 17025	02
7.	Availability of product at major chain pharmacies having minimum 20 branches with in Pakistan w.e.f January 2022 to onwards (three marks for each chain pharmacy & maximum up to 15 marks). Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum upto 15 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant document should not be part of bid.	15
8.	Production Capacity of the quoted product during last one year	05
i)	06 to 08 Batches of the quoted item	05
ii)	02 to 05 Batches of the quoted item	03
	The bidder shall provide documentary proof regarding batch history of the quoted Product	
9.	Stability Studies of the quoted product	05
i)	Accelerated Stability data of quoted item	03

ii)	Real Time stability data of quoted item	02
10.	Latest Social compliance certificate by EOBI / Social Security Registration Certificate or relevant.	06
	Total	100

NOTE: For some product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 70%.

QUALIFYING MARKS: 70 OUT OF 100 (70%)

3.Financial bids of only "Technically Qualifying Bidders" will be opened. Only the price offered lowest in each items shall be accepted.

BIDS EVALUATION CRITERION FOR SOLE AGENTS (DRUG / MEDICINES)

Failure to comply with any compulsory parameter / knockout clauses will result in "non-responsiveness of the bidder for quoted item". Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

.Original Receipt regarding payment of tender fees.

i.The bidder must possess valid Drug sale License (in case of importers).

i.The bidder will provide valid Drug Registration Certificate of the quoted product. The product having minimum two years' experience will be eligible.

.Valid GMP Certificate from country of manufacturer.

Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfil the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.

.Bio Similar studies of the quoted biological / Bio Tech products (in finished dosage form)

i.Undertaking on judicial stamp paper worth Rs. 100/- regarding "Non Declaration of Sub Standard / Spurious/Adulterated Batch" by any notified Drug Testing Laboratory of quoted item within last two years.

ii.Undertaking on Judicial Stamp Paper worth Rs. 100/- to the effect that Non- cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non- conviction from any court of law and black listing.

x.Two commercial packs as samples of quoted medicines for evaluation by the technical committee.

MARKING CRITERIA

TECHNICAL EVALUATION CRITERIA FOR SOLE AGENT

Sr. #	Description	Category Points

1	Source of API of Quoted Item	10
i)	Original Source / Research Molecule (Affidavit on firm's letter head)	10
ii)	Source Licensed by Original or accredited by FDA/WHO/ EMA (Certificate) (The bidder must provide Import record of one year (from July 2023 to June 2024) i.e. copy of GD/LC of quoted raw material source)	08
iii)	Others Source of Raw Material with Certificate of Analysis(July 2022 toonwards)	05
2	Bio Equivalence / Bio- similarity Study of Quoted Product (affidavit on Rs:100 stamp paper in case of research molecule)*	08
i)	Original Manufacturer will be awarded full marks.	08
ii)	Bio equivalence/Bio- similarity Study from any of the below mentioned labs: WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. (The firm will attach Bio- equivalence/ Bio- Similarity certificate of the finished product).	06
3	EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS	08
(A)	Past performance of quoted product with major Government Institutions during last two financial years i.e 2022- 2023 and 2023- 2024	04
i)	Supply of the quoted product Higher than the advertised quantity	04
ii)	Supply of the quoted product Equivalent to the advertised quantity	03
iii)	Supply of the quoted product at least 60% of advertised quantity	02
(B)	Past performance of quoted product with ANY GOVT/SEMI GOVT institute during last two financial years i.e. 2022- 2023 and 2023- 2024	04
i)	Supply of the quoted product Higher than the advertised quantity	04
ii)	Supply of the quoted product Equivalent to the advertised quantity	03
iii)	Supply of the quoted product at least 60% of advertised quantity	02
	The bidder shall provide verifiable documentary evidences like commercial sales Summary / supply order of the quoted product.	
4.	PREVIOUSLY PRE- QUALIFIED FIRMS WITH PUBLIC SECTOR AND SEMI GOVERNMENT PREFERABLY PESSI (DURING LAST FIVE YEARS)	15
i)	Prequalification of the quoted product / Section with Public Sector during last five years i.e from 2020 to 2024	10
ii)	Prequalification of the quoted product / Section with Semi Government preferably PESSI during last five years i.e from 2020 to 2024	15

5.	Availability of product at major chain pharmacies having minimum 20 branches with in Federal/Punjab w.e.f January 2020 to onwards (three marks for each chain pharmacy & maximum upto 15 marks). Hospital Items / Specialized Hospital Items and Anti- Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 15 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant Document should not be part of bid.	15

6.	Bidder & Manufacturer Relationship (in case of Sole Agent)	10
	Sole Agent Certificate from Manufacturer	
i)	2- 5 years	07
ii)	6 and above	10
7.	Local Market Business	
	How many years the quoted product is being marketed in Pakistan.	05
i)	2- 3 years	02
ii)	4- 5 years	03
iii)	6 years and above	05
8.	Compliance of Quality Standards of the Firm	05
i)	FDA/WHO/EMA/MDD approved	03
ii)	ISO 17025 or equivalent Certificate of manufacturing country	02
9.	Drug Testing	05
	Reports of WHO/FDA Accredited International Labs performed on the product	
i)	3 or more	05
ii)	1- 2 Labs	03
iii)	Testing by national Labs	02

10.	Export of quoted product (p.o/proforma invoice / LC copy etc) last two years	05
	Developed Countries (USA/Europe, Japan) 1-2 countries 3-5 countries 6 and above	05 01 03 05
11.	List of Technical Staff (as per requirement of licence)	05
12.	Temperature and humidity maintenance record of warehouse of the last one year	04
13.	Latest Social compliance certificate by EOBI / Social Security Registration Certificate or relevant	5
14.	Grand Total	100

NOTE: For some product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 70%.

QUALIFYING MARKS: 70 OUT OF 100 (70%)

4. Financial bids of only "Technically Qualifying Bidders" will be opened. Only the price offered lowest in each items shall be accepted.

GENERAL CONDITIONS OF CONTRACT

1. Definitions: In this Contract, the following terms shall be interpreted as indicated

against each.

a. "The Contract" means the agreement proposed to be entered into between the procuring agency and the successful bidder.

b. "The Contract Price" means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations. Price reasonability certificate that the prices quoted are not more than the prices quoted in Health Department / any other organization. The rates quoted should not be more than the trade price of the respective item.

c. "The Goods" means drug/ medicines, disposable syringes and I.V Cannulas etc. which the Supplier is required to supply to the Procuring Agency under the Contract.

d. "The Specifications" means the specifications of medicines, the offered items should be consistent with the specifications.

e. "The Services" means those services ancillary to the supply of goods, such as printing of special instructions on the label and packing, design, transportation upto CMSD, ISLAMABAD and other such obligations of the Supplier covered under the Contract.

f. The Procuring Agency: is the Islamabad Employees Social Security Institution and other IESSI Hospitals / IESSI Directorates under the administrative control of IESSI.

g. "The Consignee" means Pharmacist, In charge, Central Medical Store Depot, ISLAMABAD, for the supply order issued for medicines by the Head Office.

h. "The Supplier" means the individual or firm supplying the goods under this Contract.

2. "Eligible Bidder" The Pharmaceutical Firm as Manufacturer and Sole Agent of Foreign Principal possessing valid manufacturing license and valid drug sale license respectively as well as fulfilling other requirements contained in the Bidding Document and Evaluation Criteria are eligible to participate in the tender.

3. Application: These General Conditions shall apply to the extent that they are not inconsistent / superseded by provisions of other parts of the Contract.

4. Standards: The goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications.

5. Pack adjustment Pack adjustment of the medicines if required keeping in view packs size of the first lowest bidder will be made by IESSI.

6. Submission of Samples: Labeling and Packing of the product would be examined in

accordance with Labeling and Packing Rules 1986 of the Drugs Act 1976. The Supplier shall provide TWO (02) samples (commercial packs); free of cost along with the tender failing which the offers will not be accepted.

7. Ensuring intimation of storage arrangements: To ensure storage arrangements for the intended supplies, the Supplier shall inform the Consignee one week in advance.

8. Inspections and Test / Analysis

i) The Procuring Agency or its representative shall have the right to inspect and / or to test the goods to confirm their conformity to the specifications of the contract at no extra cost to the Procuring Agency.

ii) The inspection committee constituted by IESSI, Head Office shall inspect the quantity and specifications of medicines who will submit a report on Inspection Certificate.

iii) The supplier will be responsible for free replacement of stocks if the same is not found to be of the same specifications as required in the Invitation of Bids / Substandard / Spurious / Misbranded / Expired / near to Expiry. Moreover, it will replace the unconsumed expired stores without any further charges.

iv) The Procuring Agency's right to inspect, test and, where necessary, reject the goods after the arrival at Procuring Agency's destinations shall in no way be limited or

Waived by reason of the goods having previously been inspected, tested, and passed by the Procuring Agency or its representative.

v) Nothing in General Conditions of Contract shall in any way release the Supplier from any warranty or other obligations under this Contract.

9. Chemical and physical examination of medicines

I All the Drugs / Medicines shall be acceptable subject to chemical and physical examination. The chemical examination shall be carried out through the Drugs Testing Laboratory FEDERAL/PUNJAB. If the facility for test / analysis is not available with DTL, federal Government then the sample will be sent to Punjab through PQCB. If the test facilities are not available with the DTL, as well as NIH Islamabad then the case shall be dealt under Section 22 of Drug Act 1976.

II The Inspection Committee constituted by IESSI, Head Office shall carry out the physical examination after receipt of supplies. If the medicines supplied are found during physical examination / inspection to be against the required specifications, approved samples, etc, even if it is of standard quality, the Procuring Agency may reject the goods, and the Supplier shall either replace

the rejected goods or arrange alterations necessary for rectification of observation, to meet the required specifications free of cost. Replacement in lieu of the rejected supplies must be completed within 15 days from the date of communication of decision to the Manufacturer / Supplier by the Concerned Authority. In case after replacement or alteration, the Inspection Committee again declare the item as of against the required specifications, the supply would completely be rejected and the proportionate amount of performance security of the concerned installment would be forfeited to the IESSI account and the firm shall be blacklisted minimum under the provisions of PPRA Rules 2014. However, if the entire supplies/ installments are declared as of against the required specifications, the entire performance security shall be forfeited and department may proceed against the firm for its Blacklisting under Rule 19 of PPRA Rules 2014.

III Since Drug testing of medicines against local orders are not carried out being small orders, therefore, the firm shall be liable to provide the following with each delivery:-

1.Valid invoice / warranty of drugs
2.Lot release certificate / Batch release record
3.Undertaking with clear affirmation that the firm will be responsible for any defect /quality or adverse event / reaction reported with supplied drugs.

10. Delivery and Documents: Any erasing/cutting/crossing etc. appearing in the offer must be properly signed by the person signing the tender. Moreover all pages of the tender must be signed. Offer with any over writing in no circumstances shall be accepted. The Supplier in accordance with the terms specified in the Bidding Documents shall make delivery of the goods. The details of documents to be furnished by the Supplier are specified in Special Conditions of the Contract.
11. Insurance The supplier shall be solely for the insurance of goods subject to the contract.
12. Income Tax: All applicable taxes whether International, Federal, Provisional or local shall be borne by the supplier.;
13. Transportation: The Supplier shall arrange such transportation / cold chain maintenance of the goods as is required to prevent their damage or deterioration during transit to the final destination. The medicines shall be delivered at CMS Islamabad. In case of any subsequent/supplementary order from IESSI Directorates, the supplier shall be responsible for the delivery at consignee end. All taxes shall be borne by the Supplier. Transportation including loading / unloading of goods shall be arranged and paid by the Supplier. Maintenance of cold chain be ensured by the supplier during the transportation of heat sensitive / Biological products.

For thermolabile drugs or which storage temperature is 2- 8°C, the firm shall be

bound to produce batch wise cold chain data from source of origin and thermo log data from factory to consignee's end.

14. Incidental Services: The Supplier shall be required to provide the incidental services as specified in Special Conditions of the Contract and the cost of which should include in the total bid price.
15. Warranty Certificate: The Drugs / Medicines shall be accompanied by the necessary warranty (undertaking) in accordance with the provision of the Drugs Act, 1976 and rules framed there under. The Procuring Agency shall promptly notify the Supplier in writing of any claims arising under this warranty.
16. Payment: The method and conditions of payment to be made to the Supplier under this Contract shall be specified in Special Conditions of the Contract. The currency of payment is Pak. Rupees.

    Payment will be made by the Commissioner against bill to be submitted by the contracting firms duly supported with the inspection certificate and drug test reports. For imported items Bill of Entry is also to be provided.

17. Prices: Prices charged by the Supplier for goods delivered under the Contract shall not vary from the prices quoted by the Supplier in its bid and shall remain the same till expiry of the original bid validity period provided the Procuring Agency's request for bid validity extension.
18. Contract Amendments: No variation in or modification of the terms of the Contract shall be made except by written amendment signed by the Parties.
19. Subcontracts: The Supplier shall not be allowed to sublet the job and award subcontracts under this Contract.
20. Delays in the Supplier's Performance: Delivery of the goods shall be made by the Supplier in accordance with the time schedule prescribed by the Procuring Agency. If at any time during performance of the Contract, the Supplier should encounter conditions impeding timely delivery of the goods, the Supplier shall promptly notify the Procuring Agency in writing of the fact of the delay, its likely duration and its cause(s). The Procuring Agency may at its discretion extend the Supplier's time for performance, with liquidated damages, in which case the extension

    shall be ratified by the Procuring Agency. A delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages, unless an extension of time is agreed upon without the application

of liquidated damages.

21. Penalties/liquidated Damages: In case of late delivery beyond the stipulated period, penalty as specified in Special Conditions of Contract shall be imposed upon the Supplier. The above Late Delivery (LD) is subject to General Conditions of Contract including late delivery for reasons beyond control. Once the maximum is reached, the Procuring Agency may consider termination of the Contract. In case of supply of substandard product the destruction cost will be borne by the firm i.e. burning, Dumping, Incineration. If the firm provides substandard item and fail to provide the item the payment of risk purchase (which will be purchased by the Consignee i.e Head Office or IESSI Hospitals / Directorates) the price difference shall be paid by the Firm. Broken and damaged material will be replaced by the supplier free of cost.

22. Termination for Default: The Procuring Agency, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate the Contract in whole or in part, if the Supplier fails to deliver any or all installments of the goods within the period(s) specified in the Contract, or within any extension thereof granted by the Procuring Agency; or if the Supplier fails to perform any other obligation(s) under the Contract and if the Supplier, in the judgment of the Procuring Agency has engaged in corrupt or fraudulent practices in competing for or in executing the Contract

23. Force Majeure

Notwithstanding the provisions of general conditions of contract the Supplier shall not be liable for forfeiture of its Performance Guaranty/ bid Security, or termination/ blacklisting for default if and to the extent that its delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure. For the purposes of this clause Force Majeure means an act of God or an event beyond the control of the Supplier and not involving the Supplier's fault or negligence directly or indirectly purporting to misplanning, mismanagement and/or lack of foresight to handle the situation. Such events may include but are not restricted to acts of the Procuring Agency in its sovereign capacity, wars or revolutions, fires, floods, earthquakes, strikes, epidemics, quarantine restrictions and freight embargos. If a Force Majeure situation arises, the Supplier shall promptly notify the Procuring Agency in writing with sufficient and valid evidence of such condition and the cause thereof. The Committee constituted by

IESSI, Head Office for Redressal of grievances, shall examine the pros and cons of the case and all reasonable alternative means for completion of purchase order under the Contract and shall submit its recommendations to the competent authority. However, unless otherwise directed by the Procuring Agency in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek reasonable alternative means for performance not prevented by the Force Majeure event.

24. Termination for Insolvency

The Procuring Agency may at any time terminate the Contract by giving written notice of one month time to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. In this event, termination shall be without compensation to the Supplier, provided that such termination shall not prejudice or affect any right of action or remedy which has accrued or shall accrue thereafter to the Parties.

25. Arbitration and Resolution of Disputes: The Procuring Agency and the Supplier shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the Contract. If, after thirty (30) days from the commencement of such informal negotiations, the Procuring Agency and the Supplier have been unable to resolve amicably a Contract dispute, either party may require that the dispute be referred to the Arbitrator for resolution through arbitration. In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration. The Commissioner, IESSI or his nominee shall act as sole arbitrator. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties

26. Governing Language: The Contract shall be written in English language. All correspondence and other documents pertaining to the Contract, which are exchanged by the Parties, shall be written in English.

27. Applicable Law

This contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.

28. Notices

1 Any Notice given by one party to the other pursuant to this contract shall be sent to the other party in writing and confirmed to other party's address specified in Special Conditions of Contract.

2 A notice shall be effective when delivered or on the notice's effective date,

Whichever is later

SPECIAL CONDITION OF CONTRACT

efinitions;

i. The Procuring Agency: is the ICT Employees Social Security Institution and other Institutions under administrative control of IESSI, Head Office i.e. IESSI, institutional Hospitals/IESSI, Directorates. IESSI reserves the right to purchase full or part of the stores or ignore/scrape/cancel the tender without assigning reasons.

ii. The Supplier; is the individual or firm supplying the goods under this contract.

2.Availability: All medicines supplied to IESSI should be available at major chain pharmacies having minimum 20 branches with in Federal/Punjab.

id Security;

The bidder shall furnish, as part of its financial proposal / bid, the Bid Securities (refundable) in Pak Rupees 500,000/- of estimated price in the shape of Demand Draft in the name of COMMISSIONER IESSI shall be attached with the Technical Bid whereas its copy shall be attached with the financial bid. The financial bid found deficient of the bid Security shall not be considered. No personal cheque shall be acceptable. The previous bid Security (if any), if available, shall not be considered or carried forward. However, the bid security of any successful bidder shall be returned upon submission of Performance Guarantee and in case of unsuccessful bidder, the bid security of the bidder shall be returned.

erformance Guarantee

After signing of contract, the successful bidders shall have to deposit bank draft of the amount equal to 7% of order value as performance security in the shape of Bank guaranty in the name COMMISSIONER IESSI. The bid Security will be returned to the bidder upon submission of Performance Guaranty/Security. Performance Security shall be retained for relevant financial year. The process of release of 7% performance security shall be initiated on receipt of written request from the firm after expiry of the said financial year.

nspection.

Inspection and tests of drugs / medicine at final acceptance shall be in accordance with the conditions of contract. After delivery at CMS Plot 166 street 9 sector I/10-3 Islamabad the goods shall be inspected/examined by the Inspection

Committee, to physically check the goods in accordance with the approved sample and terms / conditions of the Contract. The Committee shall submit its inspection report to CMS Plot 166 street 9 sectors I/10-3 Islamabad. In case of any deficiency, pointed out by the Inspection Committee in the delivered medicines the Supplier shall be bound to rectify it free of cost. For imported items Bill Of Entry is also to be provided to the inspection team otherwise inspection will not be conducted to proceed further accordingly.

esting.

The samples shall be collected for analysis and send to DTL, Federal/NIH. The samples drawn for Drug Testing are to be replaced by the firm at the time of supply as per rules failing which IESSI will not be responsible for delay in payment. Testing charges of samples against the supplies will be borne by the supplying firms irrespective of the result of sample. The firm shall be bound to provide primary reference standard (s)/traceable secondary standard (s) to the concerned Drugs Testing Laboratories of DTL, /NIH as and when demanded. In case of secondary reference standard, the certificate of analysis and proof of traceability shall also be provided by the contractor.

A certificate should be furnished by the tenderers that they will be responsible for the free provision of new stores if the same are found to be substandard or at variance with the specifications give in the tender inquiry. Stores of a specifications superior to the one specified in the tender inquiry shall, however, be considered.

If the stores are declared sub- standard by DTL, /NIH, distribution shall not be carried out and the entire stock will be confiscated and destroyed and the firm shall replace the whole stock with the fresh stock free of cost and simultaneously the case shall be dealt under section 22 of Drug Act 1976. The procuring agency may take any other punitive action including forfeiture of performance security and blacklisting under Rule 19 of PPRA Rules, 2004.

elivery and Documents.

The contract will be placed for the period from the date of its issuance till 30th June, 2025 and the same would be further extendable subject to approval from competent authority on mutual consent of both of the parties. The supply period will be 20 days from the date of issue of supply order with a grace period of 05 days which will start immediately after expiry of 20 days. Any subsequent/supplementary order placed by the Head Office/Directorates/S.S. Hospitals, shall also be complied with by

the firm promptly, on the same rates as quoted/& approved by the Head Office I ESSI. The Supplier shall provide the following documents at the time of delivery of goods to Consignee' end for verification and onward submission to quarter concerned, duly completed in all respect for payment.

Following documents shall be supplied to HEAD OFFICE at the time of delivery of medicines:

(i) Original copies of Delivery Note / Challan (in duplicate) in the name of In charge where delivery is to be made, item's description, batch No(s), Registration No, manufacturing and expiry date and quantity along with pack size.

(ii) Original copies of the Supplier's invoices (in duplicate) showing warranty, in the name of Commissioner IESSI, Head Office, item's description, Batch No, Registration No, manufacturing and expiry date, quantity, pack size, per unit cost, and total amount.

i) Undertaking on judicial paper.

Following documents shall be supplied to Purchase Cell for payment

ttested copies of valid drug manufacturing licence / licenses & sale license, & drugs registration certificates shall be attached. The firm will have to provide the valid professional tax exemption certificate.

ii. NTN Certificate.

iii. Receipt 7% of order value.

iv. Valid printed original Price List of relevant tender period should be attached.

he firms providing false documents or giving misleading statements will be debarred from the current & next tenders.

Valid letter of authorization from the Foreign Principal in case of Sole Agent / Importer.

vii. Proof of updated / latest Active Taxpayer.

Proof of permission for toll manufacturing from DRAP and pre-qualification of the respective firm with IESSI.

Incidental Services

The following incidental services shall be provided and the cost of which should include in the total bid price.

a. The bidder shall supply drugs/medicines as far as possible as per tender requirement in commercial packing.

b. The following wording/insignia shall be printed in bold letters (English) on each carton, pack, bottle, strip / blister, tubes, vial / ampoule etc.
"IESSI PROPERTY NOT FOR SALE"

c. The rules for labelling and packing shall be followed as per "The Drugs (Labeling and Packing) Rules, 1986", framed under the Drugs Act, 1976. However, the name of Drug / Medicine (Generic & Brand), equally prominent, should be printed/ written in indelible ink in English on the outer cartons and on each Pack, Bottle, Strip/ Blister, Tubes etc. Besides the name and principal place of business of the Manufacturer, the drug manufacturing license No., manufacturing date, expiry date, registration No., batch No. and retail price, name of drug, dosage and instructions, should also be written on the outer carton and on the most inner container in bold letters. Tablets / Capsules shall be supplied in aluminium strip / blister pack, however, in case commercial packs of tablets / capsules are packed in bottles then the quantity of the pack shall be accepted as per quantity of commercial pack and packing in excess quantities other than commercial pack size shall not be accepted. Expiry date must be printed on each aluminum strip / blister. The syrup should be supplied in glass / pet bottle with sealed caps as per sample provided at the time of opening of tender. 2ml and less than 2ml ampoules, heat sensitive ampoules and water for injection / distilled water supplied along with antibiotic & powder vials shall be exempted from over printing however outer cartons shall be printed as "IESSI Property not for Sale". In case of non-fulfillment of these requirements the supply shall not be accepted.

d. Barcoding / QR Coding as per latest instructions of DRAP.

e. Glass ampoules having no paper label shall be exempted from printing from "IESSI PROPERTY NOT FOR SALE", however, outer carton shall be printed as "IESSI PROPERTY NOT FOR SALE".

f. In case of ampoules which are packed in tray, "IESSI PROPERTY NOT FOR SALE" shall be printed on the label of the tray and ampoules may be exempted from printing "IESSI PROPERTY NOT FOR SALE", however, outer carton shall be printed as "IESSI PROPERTY NOT FOR SALE".

g. Kleen Enema bottle shall be exempted from printing "IESSI PROPERTY NOT FOR SALE", however, the plastic cover and outer carton should be printed as "IESSI PROPERTY NOT FOR SALE".

h. Medicines with minimum of 80% shelf life for the locally manufactured shall be accepted at the time of delivery.

i. Medicines with minimum of 75% shelf life for imported medicines shall be accepted, however shelf life upto 70% shall be accepted with penalty equal to 1% of total value of the medicine per percentage point of the short fall in the prescribed shelf life.

j. Request of firm for extension in delivery period and acceptance of medicines with less shelf life shall be examined by the Purchase Committee on case to case basis.

k. If the Supplier / bidder charged the prices of incidental services separately in the financial bid and not included in the Contract price of goods, the same shall be included prior to comparison of rates with the other bidders.

9. Warranty: The drugs/medicines shall be accompanied by the necessary warranty on judicial under taking in accordance with the provision of the Drugs Act, 1976 / rules framed there under.

Payment

a) The Payment shall be in Pak Rupees.

b) The payment will be made in two parts for Phase I & Phase-II respectively on submission of documents along with Standard Quality DTL reports and Physical Inspection report carried out by the committee.

c) The laboratory test / analysis charges of sample either from DTL, Punjab or from NIH, Islamabad. shall be borne by the Supplier.

Penalties/ Liquidated Damages.

a. In case where the deliveries as per contract are not completed within stipulated period, the contract to the extent of non- delivered portion of supply may be cancelled followed by a Show Cause Notice. The amount of 7% performance Guaranty to the extent of non- delivered portion of supplies of relevant item/ items shall be forfeited. Institution may take any other punitive action according to the performance of the firm.

If the firm fails to supply the whole installments, the entire amount of Performance Guaranty/Security shall be forfeited and department may proceed against the firm for blacklisting under Rule 19 of PPRA Rules 2004 shall be followed minimum for a period of two year. Institution reserves the right to purchase the item from the 2nd- lowest firm (if any) at the risk and cost of the defaulting firm against the head office supply orders, whereas in case medicines are not supplied against local supply orders at Head Office approved rates then respective IESSI Directorates can procure the ordered medicines from any other firm at the risk and cost of non- supplying firm without gross difference of the Head Office approve rates.

b. In case where the deliveries as per contract are not completed within the time frame specified in the schedule of requirement, the Contract to the extent of non- delivered portion of supply may be cancelled followed by a Show Cause Notice and amount of Performance Guaranty to the extent of non–delivered portion of supplies of relevant item shall be forfeited and may proceed against the firm to debar for one year from future tender and also to proceed for blacklisting under Rule- 19 of PPRA Rule 2004 (amended). If the firm fails to supply the whole stock, the entire amount of Performance Guaranty/ Security shall be forfeited to the IESSI account and the firm may be blacklisted under Rule 19 of PPRA Rules 2004. Institution reserves the right to purchase the item from the 2ND - lowest firm at the risk and cost of the defaulting firm.

c. Any order placed erroneously shall have to be lifted back by the firm at its own cost.

d. The delivery period given by IESSI shall be acceptable to the firms. In case of late delivery of goods beyond the periods specified in the schedule of requirements, penalty @1% Per Day of the cost of late delivered supply shall

be imposed.

e. In case of acceptance of medicines with less shelf life by the Purchase Committee than deduction shall be made @ 1% per shortfall against 80% required shelf life

Arbitration and Resolution of Disputes: -

In case of any dispute, concerning the interpretation and / or application of this Contract shall be settled through arbitration. The Commissioner, IESSI or his nominee shall act as sole ARBITRATOR. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties.

Governing Language: The language of this Contract shall be in English.

14. Applicable Law: This Contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.

Notices

Supplier's address for notice purpose

Procuring Agency's address
For notice purposes shall be the;

_____

(Medical Advisor), IESSI, Head Office,
166 STREET 9
I/10-3
ISLAMABAD

Note: All assessments and procuring procedures i.e. receiving, opening and awarding etc. shall be governed by the Public Procurement Rules 2004 (as amended from time to time).

MANUFACTURER'S AUTHORIZATION FORM

To:

The Commissioner,
IESSI.

WHEREAS M/s.who are established and reputable Manufacturers of medicines having factory located at

_do hereby authorizeto submit a bid, and subsequently negotiate and sign the Contract with you against No.for the goods manufactured by the firm. We hereby extend our full guarantee and warranty as per Clause of the General Conditions of Contract for the goods offered for supply by the above firm against this Invitation for Bids.

{Signature on behalf of manufacturer}

Note: This letter of authority should be on the letterhead of the Manufacturer and should be signed by a person competent and having the power of attorney to bind the Manufacturer. It should be included by the bidder in its bid.

CONTRACT FORM

THIS FRAMEWORK CONTRACT is made at ----------on----------day of---

--- 2024, between IESSI (hereinafter referred to as the "Procuring Agency") of the First Part; and M/s---------- a firm registered under the laws of Pakistan and having its registered office at (hereinafter called the "Supplier") of the Second Part (hereinafter referred to individually as "Party" and collectively as the "Parties"). WHEREAS the Procuring Agency invited bids for procurement of medicines in pursuance where of M/s---------- being the Manufacturer/ Sole Agent of items (list enclosed) in Pakistan and ancillary services offered to supply the required item (s); and Whereas the Procuring Agency has accepted the bid by the Supplier for the supply of item, Along with cost per unit list enclosed.

NOW THIS CONTRACT WITNESS AS FOLLOWS:

1. In this Contract words and expressions shall have the same meanings as are respectively assigned to them in the General/ Special Conditions of this Contract hereinafter referred to as "Contract":
2. The following documents shall be deemed to form and be read and construed as integral part of this Contract, viz:-
    a. Price Schedule submitted by the bidder,
    b. Technical Specifications;

c. General Conditions of Contract;
d. Special Conditions of Contract; and
e. Procuring Agency's Award of contract; and
f. Purchase Order

3. In consideration of the payments to be made by the Procuring Agency to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Procuring Agency to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of this Contract.
4. The Procuring Agency hereby covenants to pay the Supplier in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of this Contract at the time and in the manner prescribed by this Contract.
5. M/s. hereby declares that it has not obtained or induced the procurement of any Contract, right, interest, privilege or other obligation or benefit from IESSI or any administrative subdivision or agency thereof or any other entity owned or controlled by it IESSI through any corrupt business practice.
6. Without limiting the generality of the foregoing, [the Seller/ Supplier] represents and warrants that it has fully declared the brokerage, commission, fees etc., paid or payable to anyone and not given or agreed to give and shall not give or agree to give to anyone within or outside Pakistan either directly or indirectly through any natural or juridical person, including its affiliate, agent, associate, broker, consultant, director, promoter, shareholder, sponsor or subsidiary, any commission, gratification, bribe, finder's fee or kickback, whether described as consultation fee or otherwise, with the object of obtaining or including the procurement of a Contract, right Interest, privilege or other obligation or benefit in whatsoever form from IESSI, except that which has been expressly declared pursuant hereto.
7. M/s. certifies that has made and shall make full disclosure of all agreements and arrangements with all persons in respect of or related to the transaction with IESSI and has not taken any action or shall not take any action to circumvent the above declaration, representation or warranty.
8. M/s. accepts full responsibility and strict liability for making any false declaration, not making full disclosure, misrepresenting facts or taking any action likely to defeat the purpose of this declaration, representation and warranty. It agrees that any Contract, right, interest, privilege or other obligation or benefit obtained or procured as aforesaid shall, without prejudice to any other right and remedies available to Procuring Agency under any law, Contract or other instrument, be void able at the option of Procuring Agency.
9. Notwithstanding any rights and remedies exercised by Procuring Agency in this regard,

M/s.agrees to indemnify Procuring Agency for any loss or damage incurred by it on account of its corrupt business practices and further pay compensation to Procuring Agency in an amount equivalent to ten time the sum of any commission, gratification, bribe, finder's fee or kickback given by M/s.as aforesaid for the purpose of obtaining or inducing the procurement of any Contract, right, interest, privilege or other obligation or benefit in whatsoever form from Procuring Agency.

10 In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration. Commissioner, IESSI or his nominee shall act as sole arbitrator. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties.

11. This Contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.
12. If the firms provide substandard item and fail to provide the item the payment of risk purchase, the price difference shall be paid by the Firm
13. In case of supply of substandard product the destruction cost will be borne by the firm i.e burning, Dumping, Incineration
14. If the price quoted by the firm to the IESSI are more than the T.P prices or charged from any other government institution/hospital in the country for the same financial year, in such discrepancy the firm shall be bound to refund the prices charged in excess. Affidavit to this effect is also enclosed with the contract by the firm.

IN WITNESS Whereof the Parties hereto have caused this Contract to be executed at IESSI, Head Office and shall enter into force on the day, month and year first above mentioned.

Signed/ Sealed by the Manufacturer/ authorized Person

Signed/ Sealed by Procuring Agency

1

_____ IESSI HEAD OFFICE

MEDICAL ADVISOR

2 _

BID FORM

To:

Date: No. _

The
Commissioner,
IESSI, Head
Office, Plot
No.166,street#9
Sector I/10-3
Islamabad.

Having examined the Bidding Documents, the receipt of which is hereby duly acknowledged, we, the undersigned, offer the supply and deliver the goods specified in and in conformity with the said Bidding Documents for the sum of [Total Bid Amount _], [Bid Amount in words _] or such other sums as may be ascertained in accordance with the Schedule of Prices attached herewith and made part of this bid.

We undertake, if our bid is accepted, to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements. If our bid is accepted, we shall submit 7% as performance security (in shape of bank draft) of the contract price.

We agree to abide by this bid for a period of 120 days from the date fixed for bid opening under instruction to the bidders, and it shall remain binding upon us and may be accepted at any time before the expiration of that period. Until a formal Framework Contract is prepared and executed, this bid, together with your written acceptance thereof and your notification of award shall constitute a binding Contract between us.

We understand that the Procuring Agency is not bound to accept the lowest or any bid, Procuring Agency may receive.

Name and address of bidder ----------

Dated this day of 20.

Signature (in the capacity of)

Duly authorized to sign bid for and on behalf of.

==========

DRUG SPECIFICATION PROFORMA

To,	Tender No
	Name of I
The Commissioner	Address:
ICT Employees Social Security Institution	Phone No.

ISLAMABAD, Drug Mfg/ Drug Sales Licence Validity of Licence

Sr #	IESSI #	Name of item as in IESSI Specification List	Specification of the offered item	Brand Name of the offered item	Name and Country of Manufacturer	Drug Registration No	Batch Capacity	Packing Commercial	Page No. / Location of Drug Registration letter	
1										
2										
3										
4										
5										
6										

NOTE Signature of Authorized Person:

i) Quoted item should be highlighted with yellow highlighter on drug registration certificate and invoices/ bill warranty.
iii) The firm should provide Two (02) commercial packs as representative of the supplies.

Name of Authorized Person:

Designation of Authorized Person: